



Ash A. Alizadeh, MD/PhD

Moghadam Family Professor
Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Comprehensive Cancer Center**

875 Blake Wilbur Dr
MC 6560
Stanford, CA 94305
Tel (650) 498-6000

Fax (650) 724-5203

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Nikia Earls - Administrative Assistant
Email nikiae@stanford.edu
Tel (408)594-0620

Bio

BIO

Ash A Alizadeh is the Moghadam Family Professor of Medicine, Oncology, and Hematology (by courtesy) at Stanford University, and leader of the Cancer Genomics Program at Stanford Cancer Institute. His primary research interests are in the development and application of genome technologies and computing (machine learning & data science) to a range of problems in human disease, with special focus on cancer detection, classification, monitoring, and tumor immunology. As a longstanding member of NIH Cancer Genetics (CG) Study Section, he helps the Center for Scientific Review with genome scale studies focused on cancer pathogenesis.

Dr. Alizadeh leads a group interested in techniques and methods for understanding tumor behavior at molecular, cellular, organism and population levels. In this effort, his group studies cancer genomic profiles obtained either from tumor tissues, or from noninvasive “liquid biopsies”. Using machine learning techniques, his lab studies how cellular compositional variation impacts cancer behavior and therapeutic response (e.g., <http://cibersortx.stanford.edu>, <http://precog.stanford.edu>, and <http://ecotyper.stanford.edu>), including anti-tumor immunity (<http://maria.stanford.edu>).

Dr. Alizadeh's group has helped pioneer a range of noninvasive cancer genomic techniques that enable “liquid biopsies”, including CAPP-Seq (<https://cappseq.stanford.edu>), PhasED-Seq (<https://phasedseq.stanford.edu>), and EPIC-Seq (<https://epicseq.stanford.edu>). Using such techniques work from his group focuses on the analysis of circulating nucleic acids to address problems for early cancer detection (<http://clip.stanford.edu>) and noninvasive cancer monitoring, including prediction of therapeutic response (<http://ciri.stanford.edu> & <http://direct.stanford.edu>).

Dr. Alizadeh holds a BS in Biochemistry from UCLA, an MD from Stanford Medical School, a PhD in Biophysics from Stanford, with additional training at the National Cancer Institute (NCI), the National Institutes of Health (NIH), and the Howard Hughes Medical Institute (HHMI). He has received a number of key awards for his work, including the Scholar Award from the American Society of Hematology (ASH), the Leukemia & Lymphoma Society (LLS), the V-Foundation, as well as awards from the American Red Cross, Damon Runyon Cancer Research Foundation, Doris Duke Charitable Research Foundation, among others. He is an elected member of the American Society for Clinical Investigation (ASCI), and an elected member of the Scientific Advisory Board (SAB) of the Lymphoma Research Foundation (LRF).

Dr. Alizadeh is a past-President of the American Society of Hematology (ASH) Meeting on Lymphoma Biology, a founding member of the International Lymphoma ctDNA Consortium & Working Group, and past-Chair of the Scientific Committee on Genetics & Epigenetics for the American Society of Hematology (ASH), and past-Chair the Scientific Committee on Lymphoma & Myeloma for the American Society of Clinical Oncology (ASCO). Dr. Alizadeh is a co-founder of CAPP Medical, CiberMED, and Foresight Diagnostics. Dr. Alizadeh is board certified in Medical Oncology, Hematology, and Internal Medicine, a member of the Stanford Lymphoma Program, and received the Stanford Department of Medicine Research Award in 2005. He is a member of the Scientific Advisory Board for Cell, and Scientific Editor for Blood, Cancer Discovery, Blood Cancer Discovery, and the Journal of Clinical Oncology (JCO) and Precision Oncology (PO).

CLINICAL FOCUS

- Cancer > Lymphoma
- Lymphoma
- B-Cell Chronic Lymphocytic Leukemia
- Waldenstrom Macroglobulinemia
- Burkitt Lymphoma
- Follicular Lymphoma
- Diffuse Large-Cell Lymphomas
- Leukemia, Hairy Cell
- Lymphoma, B-Cell, Marginal Zone
- Hodgkin Disease
- Medical Oncology

ACADEMIC APPOINTMENTS

- Professor, Medicine - Oncology
- Member, Bio-X
- Member, Institute for Stem Cell Biology and Regenerative Medicine
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Chair, Seminar Committee, Stanford Immunology Program, (2011- present)
- Admissions Panel, Medical Scientist Training Program, Stanford University, (2011- present)
- Admissions Panel, Stanford Medical School, (2012- present)
- Steering Committee Member & Mentor, Stanford Computational & Systems Immunology, (2012- present)

HONORS AND AWARDS

- Magna cum laude, College & Departmental Honors, UCLA (6/1993)
- NIH Research Fellow Award, NIH/NCI (6/1995)
- Research Scholar Award, HHMI-NIH (1996 1998)
- Intramural Research Award, NIH/NCI (1997 1998)
- Research Scholar Award for Outstanding Research, HHMI (1998)
- Medical Scientist Training Program Award, NIH (1996-2003)

- Sandler Fellow Award, UCSF (2003-2004)
- Franklin G. Ebaugh, Jr. Award for Outstanding Research, Dept of Medicine, Stanford (2004-2005)
- Leukemia & Lymphoma Society Special Fellow in Clinical Research, Stanford University (2010-2013)
- American Society for Clinical Oncology Career Development Award, Stanford University (2010-2013)
- Clinical Investigator Program: Fellow Award, Stanford University Medical Center (2004-2010)
- Josephine Q. Berry Faculty Scholar in Cancer Research, Stanford University (2010)
- Bent & Janet Cardan Oncology Research Fellow, Stanford University (2010)
- Gabrielle's Angel Foundation, Stanford University (2012-2015)
- Doris Duke Clinical Scientist Development Award, Stanford University (2011)
- Cancer Innovation Award, Stanford Hospital & Clinics (2012-2013)
- Damon Runyon Cancer Research Foundation Clinical Investigator Award, Stanford University (2014-2017)
- V-Foundation Scholar/Martin D Abeloff Award (1st Place), Stanford University (2014-2016)
- Celgene Young Investigator Award, Stanford University (2014-2015)
- American Society of Hematology Scholar Award, Stanford University (2015-2017)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Vice Chair, Committee on Epigenetics and Genomics, American Society of Hematology (2014 - present)
- Mentor, Lymphoma Clinical Research Mentoring Program, Lymphoma Research Foundation (2013 - present)
- Leader, Scientific Program Committee on Lymphoma, Myeloma, Plasma Cell Disorders, American Society of Clinical Oncology (2011 - 2014)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2021)
- Medical Education: Stanford University School of Medicine (2003) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2009) CA
- Residency: Stanford University Internal Medicine Residency (2006) CA
- MD, Stanford university School of Medicine , Medicine (2003)
- PhD, Stanford university School of Medicine , Biophysics/Dept of Biochemistry (2003)
- B.S., UCLA , Biochemistry (1994)

LINKS

- Alizadeh Lab: http://med.stanford.edu/labs/ash_alizadeh/
- Scholar Profile: <http://scholar.google.com/citations?user=KRkHmBIAAAAJ&hl=en>
- NIH Bibliography: <http://www.ncbi.nlm.nih.gov/sites/myncbi/arash.ash.alizadeh.1/bibliography/40471369/public/?sort=date&direction=descending>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My group's research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies.

My group develops and applies genomic biomarkers of tumor cells, whether detected through biopsy of the primary neoplasm, or noninvasively through monitoring of the bodily fluids including blood. We apply such genomic biomarkers for the early detection, diagnosis, and monitoring of diverse tumors including lymphomas and solid tumors.

We are also interested in better molecular understanding of normal tissue stem cells and their malignant tumor-initiating counterparts (cancer stem cells), toward identification of the underlying mechanisms relevant to specific cancers of the hematopoietic system. These tumors include follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma.

We have also worked to build prognostic and predictive models for clinical and therapeutic outcomes of diverse human malignancies, through large-scale bioinformatic meta-analysis of human tumor transcriptomes, including deconvolution of complex tumor admixtures including infiltrating leukocytes.

In this effort, we help build and employ tools from functional genomics, computational biology, molecular genetics, and mouse models. We are applying this knowledge toward the design of clinical trials in the treatment of patients with various malignancies, whom I care for directly or indirectly, as a clinician specializing in Medical Oncology and Hematology.

CLINICAL TRIALS

- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease, Recruiting
- Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD), Recruiting
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas, Not Recruiting
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma, Not Recruiting
- An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study, Not Recruiting
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas, Not Recruiting
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas, Not Recruiting
- Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP), Not Recruiting
- Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL, Not Recruiting

Teaching

COURSES

2022-23

- Seminar in Immunology: IMMUNOL 311 (Aut, Win, Spr)

STANFORD ADVISEES

Med Scholar Project Advisor

Karan Kathuria

Doctoral Dissertation Reader (AC)

Kevin Liu, Santiago Sanchez, Emily Shen, William Shi

Postdoctoral Faculty Sponsor

Julia Kuehn, Caroline Lee, Troy Noordenbos, Lena Osswald, Takeshi Sugio, Steven Wang

Doctoral Dissertation Advisor (AC)

Nick Phillips

Doctoral Dissertation Co-Advisor (AC)

Shuyu Shi

Postdoctoral Research Mentor

Amirsaman Ashtari, Takeshi Sugio, Rui Wang

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Biochemistry (Phd Program)
- Biophysics (Phd Program)
- Cancer Biology (Phd Program)
- Immunology (Phd Program)
- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Field-effect-informed urine liquid biopsy for bladder cancer.** *Cell*
Shi, W. Y., Liu, K. J., Esfahani, M. S., Mach, K. E., Phillips, N. A., Almanza, D., Bajpai, R. K., Schroers-Martin, J. G., Trabanino, L., Lee, T. J., La, V., Rodriguez, G., Holton, et al
2026
- **Optimizing First-Line Therapy for Diffuse Large B-Cell Lymphoma** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Alizadeh, A. A.
2025; 23: 21-23
- **Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Roschewski, M., Kurtz, D. M., Westin, J. R., Lynch, R. C., Gopal, A. K., Alig, S. K., Sworder, B. J., Cherng, H. J., Kuffer, C., Blair, D., Brown, K., Goldstein, J. S., Schultz, et al
2025: 101200JCO2501534
- **An ultrasensitive method for detection of cell-free RNA.** *Nature*
Nesselbush, M. C., Luca, B. A., Jeon, Y. J., Jabara, I., Meador, C. B., Garofalo, A., Binkley, M. S., Hui, A. B., van 't Erve, I., Xu, N., Shi, W. Y., Liu, K. J., Sugio, et al
2025
- **Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply.** *The New England journal of medicine*
Hamilton, M. P., Miklos, D. B., Alizadeh, A. A.
2024; 391 (9): 870-871
- **Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.** *The New England journal of medicine*
Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., Kang, X., Olsen, M. N., Good, Z., Dahiya, S., Frank, M. J., Sahaf, B., Mackall, et al
2024; 390 (22): 2047-2060
- **Cell-free RNA analysis for non-invasive cancer detection and characterization**
Nesselbush, M. C., Luca, B. A., Jeon, Y., Jabara, I., Meador, C. B., Binkley, M. S., Xu, N., Hui, A. B., Garofalo, A., Shi, W. Y., Liu, K. J., Sugio, T., Kastelowitz, et al
AMER ASSOC CANCER RESEARCH.2024
- **Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.** *Nature*

- Alig, S. K., Esfahani, M. S., Garofalo, A., Li, M. Y., Rossi, C., Flerlage, T., Flerlage, J. E., Adams, R., Binkley, M. S., Shukla, N., Jin, M. C., Olsen, M., Telenius, et al
2023
- **Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin.** *The New England journal of medicine*
Palmer, A. C., Kurtz, D. M., Alizadeh, A. A.
2023; 389 (8): 764-766
 - **Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors.** *Cancer discovery*
Schroers-Martin, J. G., Soo, J., Brisou, G., Scherer, F., Kurtz, D. M., Sworder, B. J., Khodadoust, M. S., Jin, M. C., Bru, A., Liu, C. L., Stehr, H., Vineis, P., Natkunam, et al
2023
 - **From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment.** *Cell*
Swanson, K., Wu, E., Zhang, A., Alizadeh, A. A., Zou, J.
2023
 - **Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.** *Cancer cell*
Sworder, B. J., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Shahrokh Esfahani, M., Olsen, M. N., Hamilton, J., Hosoya, H., Hamilton, M., Spiegel, et al
2022
 - **Molecular Monitoring of Lymphomas.** *Annual review of pathology*
Schroers-Martin, J. G., Alig, S., Garofalo, A., Tessoulin, B., Sugio, T., Alizadeh, A. A.
2022
 - **Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms.** *Blood*
de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A. J., Dogan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., Morin, R. D., Nadel, B., Pileri, et al
2022
 - **Inferring gene expression from cell-free DNA fragmentation profiles.** *Nature biotechnology*
Esfahani, M. S., Hamilton, E. G., Mehrmohamadi, M., Nabet, B. Y., Alig, S. K., King, D. A., Steen, C. B., Macaulay, C. W., Schultz, A., Nesselbush, M. C., Soo, J., Schroers-Martin, J. G., Chen, et al
2022
 - **Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.** *Nature biotechnology*
Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., Schultz, A., Jin, M. C., Scherer, F., Garofalo, A., Macaulay, C. W., Hamilton, E. G., Chen, et al
2021
 - **Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Alig, S. n., Macaulay, C. W., Kurtz, D. M., Dührsen, U. n., Hüttmann, A. n., Schmitz, C. n., Jin, M. C., Sworder, B. J., Garofalo, A. n., Shahrokh Esfahani, M. n., Nabet, B. Y., Soo, J. n., Scherer, et al
2021: JCO2002573
 - **The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma.** *Cancer cell*
Steen, C. B., Luca, B. A., Esfahani, M. S., Azizi, A., Sworder, B. J., Nabet, B. Y., Kurtz, D. M., Liu, C. L., Khameneh, F., Advani, R. H., Natkunam, Y., Myklebust, J. H., Diehn, et al
2021
 - **Atlas of clinically distinct cell states and ecosystems across human solid tumors.** *Cell*
Luca, B. A., Steen, C. B., Matusiak, M., Azizi, A., Varma, S., Zhu, C., Przybyl, J., Espín-Pérez, A., Diehn, M., Alizadeh, A. A., van de Rijn, M., Gentles, A. J., Newman, et al
2021
 - **Integrating genomic features for non-invasive early lung cancer detection.** *Nature*
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Jin, et al
2020; 580 (7802): 245-251

- **Integrating genomic features for non-invasive early lung cancer detection** *NATURE*
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., Liu, C., Hui, A. B., Jin, et al
2020
- **Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.** *Cell*
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H. n., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Almanza, D. n., Stehr, H. n., Gojenola, et al
2020
- **Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.** *Cell*
Kurtz, D. M., Esfahani, M. S., Scherer, F., Soo, J., Jin, M. C., Liu, C. L., Newman, A. M., Duhrsen, U., Huttmann, A., Casasnovas, O., Westin, J. R., Ritgen, M., Bottcher, et al
2019
- **Determining cell type abundance and expression from bulk tissues with digital cytometry** *NATURE BIOTECHNOLOGY*
Newman, A. M., Steen, C. B., Liu, C., Gentles, A. J., Chaudhuri, A. A., Scherer, F., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D., Diehn, M., Alizadeh, A. A.
2019; 37 (7): 773-+
- **Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA** *CANCER DISCOVERY*
Dudley, J. C., Schroers-Martin, J., Lazzareschi, D., Shi, W., Chen, S. B., Esfahani, M. S., Trivedi, D., Chabon, J. J., Chaudhuri, A. A., Stehr, H., Liu, C., Lim, H., Costa, et al
2019; 9 (4): 500–509
- **Determining cell type abundance and expression from bulk tissues with digital cytometry.** *Nature biotechnology*
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F. n., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D. n., Diehn, M. n., Alizadeh, A. A.
2019
- **Predicting HLA class II antigen presentation through integrated deep learning.** *Nature biotechnology*
Chen, B. n., Khodadoust, M. S., Olsson, N. n., Wagar, L. E., Fast, E. n., Liu, C. L., Muftuoglu, Y. n., Sworder, B. J., Diehn, M. n., Levy, R. n., Davis, M. M., Elias, J. E., Altman, et al
2019
- **Analysis of Urinary Cell-free DNA for Early Detection and Surveillance of Bladder Cancer**
Dudley, J., Schroers-Martin, J., Lazzareschi, D., Shi, W., Chen, S., Liao, J., Alizadeh, A., Diehn, M.
ELSEVIER SCIENCE INC.2018: 968
- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018; 36 (28): 2845-+
- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018: JCO2018785246
- **B cell lymphomas present immunoglobulin neoantigens.** *Blood*
Khodadoust, M. S., Olsson, N. n., Chen, B. n., Sworder, B. n., Shree, T. n., Liu, C. L., Zhang, L. n., Czerwinski, D. K., Davis, M. M., Levy, R. n., Elias, J. E., Alizadeh, A. A.
2018
- **Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA** *SCIENCE TRANSLATIONAL MEDICINE*
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., Zhou, L., Glover, C., Visser, et al
2016; 8 (364)

- **Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients** *NATURE COMMUNICATIONS*
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., Harding, T. C., Durkin, K. A., Otterson, et al
2016; 7
- **Integrated digital error suppression for improved detection of circulating tumor DNA** *NATURE BIOTECHNOLOGY*
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., Zhou, L., Carter, J. N., West, et al
2016; 34 (5): 547-555
- **The prognostic landscape of genes and infiltrating immune cells across human cancers** *NATURE MEDICINE*
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., Diehn, M., West, R. B., Plevritis, et al
2015; 21 (8): 938-945
- **Toward understanding and exploiting tumor heterogeneity** *NATURE MEDICINE*
Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., Esteller, M., Fitzgerald, R., Korb, et al
2015; 21 (8): 846-853
- **Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.** *Blood*
Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., Takahashi, K., Glover, C., Keane, C., Kihira, S., Visser, B., Callahan, J., Kong, et al
2015; 125 (24): 3679-3687
- **Robust enumeration of cell subsets from tissue expression profiles.** *Nature methods*
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., Alizadeh, A. A.
2015; 12 (5): 453-457
- **Robust enumeration of cell subsets from tissue expression profiles** *NATURE METHODS*
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., Alizadeh, A. A.
2015; 12 (5): 453-?
- **Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.** *Proceedings of the National Academy of Sciences of the United States of America*
Green, M. R., Kihira, S., Liu, C. L., Nair, R. V., Salari, R., Gentles, A. J., Irish, J., Stehr, H., Vicente-Dueñas, C., Romero-Camarero, I., Sanchez-Garcia, I., Plevritis, S. K., Arber, et al
2015; 112 (10): E1116-25
- **Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.** *Proceedings of the National Academy of Sciences of the United States of America*
Green, M. R., Kihira, S., Liu, C. L., Nair, R. V., Salari, R., Gentles, A. J., Irish, J., Stehr, H., Vicente-Dueñas, C., Romero-Camarero, I., Sanchez-Garcia, I., Plevritis, S. K., Arber, et al
2015; 112 (10): E1116-25
- **FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution** *BIOINFORMATICS*
Newman, A. M., Bratman, S. V., Stehr, H., Lee, L. J., Liu, C. L., Diehn, M., Alizadeh, A. A.
2014; 30 (23): 3390-3393
- **Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.** *Journal of clinical oncology*
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timmerman, et al
2014; 32 (17): 1797-1803
- **Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma** *NATURE COMMUNICATIONS*
Green, M. R., Vicente-Duenas, C., Romero-Camarero, I., Liu, C. L., Dai, B., Gonzalez-Herrero, I., Garcia-Ramirez, I., Alonso-Escudero, E., Iqbal, J., Chan, W. C., Campos-Sanchez, E., Orfao, A., Pintado, et al
2014; 5
- **An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.** *Nature medicine*

- Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, et al
2014; 20 (5): 548-554
- **An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage** *NATURE MEDICINE*
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, et al
2014; 20 (5): 552-558
 - **Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.** *Blood*
Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Kihira, S., Liu, C. L., Kela, I., Hopmans, E. S., Myklebust, J. H., Ji, H., Plevritis, S. K., Levy, R., Alizadeh, et al
2013; 121 (9): 1604-1611
 - **Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma** *Cell*
Chao, M. P., Majeti R.
2010; 142 (5): 699-713
 - **Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Alizadeh, A. A., Gentles, A. J., Lossos, I. S., Levy, R.
2009; 360 (26): 2794-2795
 - **Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling** *NATURE*
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. G., Sabet, H., Tran, T., Yu, X., Powell, J. I., Yang, L. M., Marti, et al
2000; 403 (6769): 503-511
 - **Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEPA) in newly diagnosed CD30-positive peripheral T-cell lymphomas with integrated ctDNA analysis: Results of the phase 2 CHEPA trial.**
Trneny, M., Klener, P., Michalka, J., Belada, D., Mocikova, H., Obr, A., Steinerova, K., Duras, J., Benesova, K., Janikova, A., Malarikova, D., Sykorova, A., Ptacnik, et al
LIPPINCOTT WILLIAMS & WILKINS.2026
 - **Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma.** *Blood cancer discovery*
Shipp, M. A., Staudt, L. M., Hodson, D. J., Scott, D. W., Zhao, W. L., Dalla-Favera, R., Alizadeh, A. A., Morin, R. D.
2026: OF1-OF12
 - **Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Stepan, L., Ansari, S., Abramson, J. S., Okal, A., Dell'Aringa, J., Thompson, E. G., Crotta, A., Chow, V. A., Kamdar, M., Solomon, S. R., Johnston, P. B., Glass, B., Mutsaers, et al
2026: JCO2503051
 - **Cell-free RNA changes precede symptomatic radiation pneumonitis in cancer patients receiving thoracic radiotherapy**
Jabara, I., Kastelowitz, N., Nesselbush, M., Phillips, N., Binkley, M. S., Bonilla, R. F., Liu, K., Jiang, A., Kovalchuk, N., Alizadeh, A. A., Diehn, M.
AMER ASSOC CANCER RESEARCH.2026
 - **Roadmap for developing MRD as an early endpoint for drug approval in lymphoma.** *Seminars in hematology*
Goldstein, J. S., Wang, S. X., Chamuleau, M. E., Alizadeh, A. A.
2026
 - **DNASE1L3 Deficiency With Novel Missense Variant: Enzymatic and Plasma Fragmentomic Evidence of Pathogenicity and Partial Response to JAK Blockade** *ACR OPEN RHEUMATOLOGY*
Tenorio, A., Sugio, T., Cheng, J., Bonner, D. E., Esfahani, M., Kasinathan, S., Hsu, J. J., Moyer, A., Vera, L., Carter, J., Reuter, C. M., Marwaha, S., Balboni, et al
2026; 8 (2)
 - **Recurrent ciliary alterations under neoadjuvant selection are associated with inferior breast cancer outcomes**
Ransohoff, J. D., Carleton, M., Barroso, S., Phillips, N., Demeter, J., Goldstein, J., Maltos, A., Khodadoust, M., Ford, J., Kurian, A., Bean, G., Diehn, M., Jackson, et al
AMER ASSOC CANCER RESEARCH.2026

- **Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.** *Cancer discovery*
Aoki, T., Duns, G., Rai, S., Jiang, A., Lytle, A., Yin, Y., Kishida, M., Yu Li, M., Lee, C., Smorra, D., Hilton, L. K., Healy, S., Alig, et al
2026
- **Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Nilsson, M. B., Le, X., Poteete, A., Yu, X., He, J., Huang, Q., Shibata, Y., Liu, X., Moran, C., Alizadeh, A. A., Diehn, M., Wakelee, H., Almanza, et al
2026
- **Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.** *Leukemia & lymphoma*
Klebaner, D., Park, N. J., Marar, M., Frank, M., Hiniker, S. M., Hoppe, R. T., Schroers-Martin, J., Advani, R. H., Alizadeh, A. A., Bharadwaj, S., Miklos, D., Dahiya, S., Binkley, et al
2025: 1-8
- **Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Wang, S., Nijland, M., Strobbe, L., Oosterveld, M., Boersma, R., Koene, H., Klerk, C., de Jongh, E., Koster, A., Pruijt, H., van der Poel, M., van Werkhoven, E., Zanders, et al
2025: JCO2501712
- **Double-dose axicabtagene ciloleucef (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (rLBCL): Interim results from a Phase 1b study**
Lee, D., Rodrigues, K., Rana, M., Kozy, K., Salazar, S., Jensen, A., Desai, M., Mallampet, J., Lohman, C., Huang, Y., Kang, X., Tian, F., Mutter, et al
ELSEVIER.2025: 671-672
- **Spatial anatomical genomic heterogeneity and aberrant somatic hypermutation define clonal evolution pathways that predict treatment resistance in aggressive B-cell lymphomas**
Goldstein, J., Wang, S., Tessoulin, B., Liu, C., Scherer, F., Le Gouill, S., Chamuleau, M., Nijland, M., Diehn, M., Kurtz, D., Alizadeh, A.
ELSEVIER.2025: 354-355
- **Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA**
Ashtari, A., Mutter, J., Tessoulin, B., Rossi, C., Boegeholz, J., Goldstein, J., Klanova, M., Kuehn, J., Alig, S., Schroers-Martin, J., Liu, C., Olsen, M., Kang, et al
ELSEVIER.2025: 1789-1790
- **Precise-HL trial: Personalized reduction of chemotherapy intensity through ctDNA evaluation in advanced Hodgkin lymphoma**
Lynch, R., Russler-Germain, D., Schroers-Martin, J., Moskowitz, A., Merryman, R., Borogovac, A., Du, H., Rasmussen, H., Advani, R., Alizadeh, A., Armand, P., Bartlett, N., Herrera, et al
ELSEVIER.2025: 5408-5409
- **Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naive follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis**
Lynch, R., Poh, C., Shadman, M., Till, B., Di, M., Ujjani, C., Raghunathan, V., Smith, S., Maloney, D., Gausman, D., Rasmussen, H., Russler-Germain, D., Fehniger, et al
ELSEVIER.2025: 3591-3592
- **A unified spatial & molecular atlas of anatomically restricted large B-cell lymphomas defines stereotyped cell ecosystems**
Noordenbos, T., De Groen, R., De Groot, F., Dekker, T., De Haan, L., Kret, E., Blommers, S., Jansen, P., Shi, J., Shi, S., De Miranda, N., Diehn, M., Esfahani, et al
ELSEVIER.2025: 3555-3556
- **Longitudinal circulating tumor DNA dynamics during & after first-line therapy in a national cohort of large B-cell lymphomas**
Wang, S., Nijland, M., Bilgin, Y., Sandberg, Y., Bohmer, L., Visser, O., De Graauw, N., Ludwig, I., Van Zaanen, H., Tromp, Y., Mous, R., Koster, A., De Jongh, et al
ELSEVIER.2025: 474-475
- **Tracing malignant precursor mutations and their cellular origins in blood and bone marrow of primary central nervous system lymphomas by ultrasensitive genomic profiling**
Kuehn, J., Klingler, C., Weinschenk, S., Mutter, J., Hummel, F., Rapp, J., Lauer, E., Ranganathan, L., Bleul, S., Alig, S., Prinz, M., Duyster, J., Sankowski, et al

ELSEVIER.2025: 458-459

- **Multimodal discovery of distinct tumor ecosystems for classic Hodgkin lymphoma**
Su, S., Subramanian, A., Flerlage, T., Flerlage, J., Rossi, C., Alig, S., Younes, S., Silva, O., Luna-Fineman, S., Park, N., Noordenbos, T., Schroers-Martin, J., Moding, et al
ELSEVIER.2025: 1783-1784
- **Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling**
Mutter, J., Klanova, M., Phillips, N., Sugio, T., Esfahani, M., Schroers-Martin, J., Alig, S., Hamilton, M., Sworder, B., Tessoulin, B., Boegeholz, J., Rossi, C., Shi, et al
ELSEVIER.2025: 5330-5331
- **Distinct genomic landscape & response dynamics of HIV-associated lymphomas identified by integrated noninvasive host and virome profiling**
Shi, S., Lurain, K., Schroers-Martin, J., Garofalo, A., Mutter, J., Sugio, T., Jun, S., Kang, X., Tian, F., Liu, C., Olsen, M., Wilson, W., Diehn, et al
ELSEVIER.2025: 5320-5321
- **Molecular determinants of therapeutic response to nivolumab in Relapsed/Refractory PTCL: An integrated multiomic study of A phase II investigator-initiated trial**
Sugio, T., Jun, S., Goto, H., Kameoka, Y., Yamamoto, G., Fujita, J., Kitawaki, T., Suzuki, R., Olsen, M., Liu, C., Izutsu, K., Shibayama, H., Suzumiya, et al
ELSEVIER.2025: 5414-5415
- **A pharmacokinetic/pharmacodynamic model predicts tumor debulking improves CAR T-cell efficacy in Large B-Cell Lymphoma. *Blood cancer discovery***
Pomeroy, A. E., Sworder, B. J., Plana, D., Cao, Y., Alizadeh, A. A., Palmer, A. C.
2025
- **CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. *Research square***
Hamilton, M. P., Phillips, N., Noordenbos, T., Boegeholz, J., Sugio, T., Sworder, B. J., Alig, S. K., Good, Z., Schroers-Martin, J. G., Tamaresis, J., Esfahani, M. S., Lu, Y., Olsen, et al
2025
- **A Refined Continuous Individualized Risk Index (CIRI2-CLL) for Accurately Predicting Outcomes after Limited-Duration CLL Therapy**
Zhang, C., Al-Sawaf, O., Esfahani, M. S., Robrech, S., Tausch, E., Schilhabel, A., Ritgen, M., Schneider, C., Peifer, M., Kate, A. P., Seymour, J. F., Jiang, Y., Eichhorst, et al
KARGER.2025
- **Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC**
Coyne, Z., Kurtz, D. M., Khan, S., Feng, J., Waddell, T. K., Yasufuku, K., Saffiedine, N., Ko, M., Donahoe, L., Pierre, A., Keshavjee, S., Rabey, M. R., Le, et al
ELSEVIER SCIENCE INC.2025
- **Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma. *Nature communications***
Subramanian, A., Su, S., Flerlage, J., Alig, S., Younes, S., Marks, L. J., Pinnix, C., Vega, F., Steiner, R., Kumar, P., Mocikova, H., Sykorova, A., Prochazka, et al
2025; 16 (1): 8473
- **Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response. *JTO clinical and research reports***
van 't Erve, I., Blanchard, I., Pagtama, J. Y., Holmes Tisch, A. J., Alizadeh, A. A., Ramchandran, K., Wakelee, H. A., Padda, S. K., Diehn, M., Neal, J. W.
2025; 6 (9): 100877
- **Treatment Kinetics and Local Response during and after Bridging Radiotherapy prior to CAR-T Cell Therapy for Lymphomas**
Klebaner, D., Park, N. J., Marar, M., Frank, M., Hiniker, S. M., Hoppe, R. T., Schroers-Martin, J., Advani, R. H., Alizadeh, A. A., Bharawadaj, S., Miklos, D., Dahiya, S., Binkley, et al
ELSEVIER SCIENCE INC.2025: S86
- **Unhuddle: a heuristic method for deconvolution of shared border signal in image-based spatial proteomics**
Noordenbos, T., Shi, J., Sugio, T., Liu, C. L., Diehn, M., De Miranda, N., Vermaat, J., Esfahani, M., Alizadeh, A.
SPRINGER.2025: S335

- **Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.** *Nature communications*
Strati, P., Feng, L., Westin, J. R., Nair, R., Fayad, L. E., Rodriguez, M. A., Chihara, D., Malpica, L., Henderson, J., Gallardo, M., Rivera, M., Wang, I., Bolshakova, et al
2025; 16 (1): 7300
- **Spatially defining T-cell clonal evolution in post-neoadjuvant breast cancer and association with molecular residual disease**
Ransohoff, J., Carleton, M. A., Barroso, S., Bean, G., Maltos, A., Ford, J., Duran, G., Khodadoust, M., Telli, M. L., Alizadeh, A. A., Kurtz, D. M.
AMER ASSOC CANCER RESEARCH.2025
- **Circulating tumor DNA clearance by neoadjuvant chemotherapy or breast surgery detected using an ultrasensitive ctDNA MRD assay in early breast cancer**
Cabel, L., An, J., Kurtz, D., Ross, D., Dikoglu, E., Moiso, E., Murphy, K., Szuhany, K., Stowell, S., Maloney, D., Zamora-Chavez, G., Schultz, A., Scher, et al
AMER ASSOC CANCER RESEARCH.2025: P20125
- **Enhanced spatial detection of post-neoadjuvant breast cancer minimal residual disease by tissue-based Cancer Personalized Profiling by Deep Sequencing**
Ransohoff, J., Carleton, M. A., Barroso, S., Bean, G., Maltos, A., Ford, J., Duran, G., Khodadoust, M., Telli, M. L., Alizadeh, A. A., Kurtz, D. M.
AMER ASSOC CANCER RESEARCH.2025
- **Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial**
Wang, S., Nijland, M., Strobbe, L., Oosterveld, M., Boersma, R., Koene, H. R., Klerk, C., De Jongh, E., Koster, A., Pruijt, H., Van Der Poel, M., Van Werkhoven, E. D., Dinmohamed, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Machine-guided dual-objective protein engineering for deimmunization and therapeutic functions.** *Cell systems*
Wolfsberg, E., Paul, J. S., Tycko, J., Chen, B., Bassik, M. C., Bintu, L., Alizadeh, A. A., Gao, X. J.
2025: 101299
- **Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.** *Cancer discovery*
Moding, E. J., Shahrokh Esfahani, M., Jin, C., Hui, A. B., Nabet, B. Y., Liu, Y., Chabon, J. J., Binkley, M. S., Kurtz, D. M., Hamilton, E. G., Chaudhuri, A. A., Liu, C. L., Li, et al
2025: OF1-OF21
- **IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.** *Nature communications*
Domizi, P., Sarno, J., Jager, A., Merchant, M., Pacheco, K. Z., Yamada-Hunter, S. A., Rotiroti, M. C., Liu, Y., Baskar, R., Reynolds, W. D., Sworder, B. J., Sahaf, B., Bendall, et al
2025; 16 (1): 3800
- **Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy.** *Blood cancer discovery*
Goldstein, J. S., Phillips, N. A., Alizadeh, A. A.
2025: OF1-OF4
- **CANARY-TF: an improved copy number and tumor fraction estimator for liquid biopsy applications**
Almanza, D., Sugio, T., Hamilton, E., Kurtz, D., Diehn, M., Esfahani, M., Alizadeh, A. A.
AMER ASSOC CANCER RESEARCH.2025
- **Enhanced detection of pancreatic cancer through methylation-based liquid biopsy: insights into tumor heterogeneity, early alterations, and stromal contributions**
Wang, R., Almanza, D., Olsen, M., Kang, X., King, D., Diehn, M., Alizadeh, A.
AMER ASSOC CANCER RESEARCH.2025
- **Defining spatial molecular residual disease by personalized tumor tissue profiling**
Ransohoff, J. D., Carleton, M. A., Barroso, S., Phillips, N., Maltos, A., Bean, G., Goldstein, J., Gunaratne, C., Hosoya, H., Duran, G., Khodadoust, M., Ford, J., Tibshirani, et al
AMER ASSOC CANCER RESEARCH.2025
- **Improved non-invasive gene expression inference using advanced machine learning**
Mutter, J. A., Ashtari, A., Phillips, N., Tessoulin, B., Boegeholz, J., Rossi, C., Le Gouill, S., Diehn, M., Esfahani, M., Alizadeh, A. A.

AMER ASSOC CANCER RESEARCH.2025

● **Urine cell-free RNA analysis for bladder cancer detection and monitoring**

Liu, K. J., Shi, W. Y., Nesselbush, M. C., Phillips, N., Luca, B., Bajpai, R., Jabara, I., Mach, K. E., Hoerner, C. R., Cheng, J., Wang, R., Esfahani, M., Almanza, et al

AMER ASSOC CANCER RESEARCH.2025

● **The effect of ibrutinib on the myeloid cell compartment in CNS lymphoma.** *Leukemia*

Kuehn, J. C., Neidert, N. N., Zhang, J., Mutter, J., Alig, S., Klingler, C., Hummel, F., Ranganathan, L., Bleul, S., Beck, J., Prinz, M., Diehn, M., Alizadeh, et al

2025

● **Guiding clinical management of patients with CNS lymphomas by minimal-invasive detection of ctDNA in cerebrospinal fluid.** *Leukemia*

Weinschenk, S., Philipp, U., Kuehn, J. C., Mueller, K., Fauser, J., Boeckle, D., Gebhard, I., Hinz, M., Neidert, N., Bleul, S., Lauer, E. M., Mutter, J. A., Alig, et al

2025

● **Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.** *Blood*

Tumuluru, S., Godfrey, J. K., Cooper, A., Yu, J., Chen, X., MacNabb, B., Venkataraman, G., Zha, Y., Pelzer, B., Song, J. Y., Duns, G., Sworder, B., Raj, et al

2025

● **Circulating tumor DNA kinetics identify prodynorphin signaling as a target to radiosensitize non-small cell lung cancer**

Wang, Z., Hui, A. B., Alizadeh, A. A., Diehn, M., Moding, E. J.

AMER ASSOC CANCER RESEARCH.2025

● **Optimization of leptomeningeal carcinomatosis treatment in lung cancer using cerebrospinal fluid tumor-derived DNA**

Nanjo, S., Tej, A., Jin, M., Yano, S., Hui, A., Nagpal, S., Gephart, M., Alizadeh, A., Diehn, M.

WILEY.2025: 1891

● **Anatomic Genetic Heterogeneity Is Uncovered By Concurrent Cell-Free DNA and Tissue Profiling and Predicts Treatment Resistance in Diffuse Large B-Cell Lymphoma**

Goldstein, J. S., Scherer, F., Sworder, B. J., Diehn, M., Kurtz, D., Alizadeh, A. A.

ELSEVIER.2024: 4357-4358

● **Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA**

Sugio, T., Esfahani, M., Jun, S., Sworder, B. J., Hamilton, M. P., Hosoya, H., Olsen, M., Kang, X., Liu, C., Tian, F., Miklos, D. B., Kurtz, D., Diehn, et al

ELSEVIER.2024: 2223-2224

● **Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL**

Goldstein, J. S., Roschewski, M., Kim, W., Yoon, S., Kim, S., Westin, J. R., Lynch, R. C., Alig, S. K., Close, S., Chabon, J., Rossi, D., Wilson, W. H., Kurtz, et al

ELSEVIER.2024: 651-652

● **Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas**

Sugio, T., Nesselbush, M., Shukla, N., Garofalo, A., Mutter, J. A., Esfahani, M., Alig, S. K., Shi, S., Noordenbos, T., Hamilton, M. P., Rossi, C., Tian, F., Liu, et al

ELSEVIER.2024: 454-455

● **Investigating Treatment Kinetics and Local Response during and after Bridging Radiotherapy Prior to CAR-T Cell Therapy for Lymphomas**

Klebaner, D., Park, N., Marar, M., Frank, M. J., Hiniker, S., Hoppe, R. T., Schroers-Martin, J. G., Advani, R. H., Alizadeh, A. A., Bharadwaj, S., Miklos, D. B., Dahiya, S., Binkley, et al

ELSEVIER.2024: 7130-7131

● **Acquired Immunodeficiency Landscapes Via Integrated Noninvasive Viral & Immune Profiling in HIV-Associated Lymphoproliferative Disease**

Shi, S., Lurain, K., Schroers-Martin, J. G., Garofalo, A., Mutter, J. A., Sugio, T., Kang, X., Tian, F., Liu, C., Olsen, M., Wilson, W. H., Diehn, M., Roschewski, et al

ELSEVIER.2024: 1157-1158

- **Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid**
Weinschenk, S., Philipp, U., Kuehn, J. C., Mueller, K. J., Fauser, J., Boeckle, D., Gebhard, I., Hinz, M., Neidert, N. N., Bleul, S., Lauer, E. M., Mutter, J. A., Alig, et al
ELSEVIER.2024: 1583-1584
- **Resolving the Microarchitecture of Classic and Transformed Follicular Lymphoma By Single Cell Alignment to Spatial Transcriptomes**
Noordenbos, T., Schroers-Martin, J. G., Hamilton, M. P., Jun, S., Sugio, T., Sworder, B. J., Steen, C., Olsen, M., Liu, C., Newman, A., Howitt, B., Natkunam, Y., Miklos, et al
ELSEVIER.2024: 2993-2994
- **Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma**
Boegeholz, J., Rossi, C., Goldstein, J. S., Alig, S. K., Garofalo, A., Esfahani, M., Schroers-Martin, J. G., Liu, C., Olsen, M., Kang, X., Tian, F., Kurtz, D., Andre, et al
ELSEVIER.2024: 565-566
- **High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage CHL Treated with Pembrolizumab plus AVD**
Lynch, R. C., Alig, S. K., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., Shadman, M., Till, B. G., Raghunathan, V., Tseng, Y. D., Ottemiller, S., Joy, B., Fessel, et al
ELSEVIER.2024: 3051-3052
- **Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders**
Schroers-Martin, J. G., Garofalo, A., Shi, S., Soo, J., Luikart, H., Sworder, B. J., Boegeholz, J., Kang, X., Olsen, M., Liu, C., Tian, F., Skoda, A., Gamino, et al
ELSEVIER.2024: 648-649
- **Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleuce (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study**
Stepan, L., Ansari, S., Okal, A., Dell'Aringa, J., Thompson, E. G., Crotta, A., Chow, V. A., Abramson, J. S., Kamdar, M., Solomon, S. R., Johnston, P. B., Glass, B., Mutsaers, et al
ELSEVIER.2024: 72-74
- **The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures**
Kuehn, J. C., Neidert, N. N., Zhang, J., Mutter, J. A., Alig, S. K., Klingler, C., Hummel, F., Bleul, S., Ranganathan, L., Beck, J., Prinz, M., Diehn, M., Alizadeh, et al
ELSEVIER.2024: 4374-4375
- **Comprehensive Characterization of the Cell States and Ecosystems in Classic Hodgkin Lymphoma Using Single-Cell RNA-Seq, Digital Deconvolution, and Machine Learning**
Su, S., Subramanian, A., Flerlage, T., Flerlage, J. E., Rossi, C., Noordenbos, T., Schroers-Martin, J. G., Moding, E. J., Hoppe, R. T., Advani, R. H., Natkunam, Y., Alizadeh, A. A., Binkley, et al
ELSEVIER.2024: 4369-4370
- **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
ELSEVIER.2024: 96-97
- **The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL**
Kambhampati, S., Goldstein, J. S., Buller, S., Roschewski, M., Alizadeh, A. A., Thiruvengadam, N.
ELSEVIER.2024: 2276-2277
- **Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleuce in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study**
Lee, D., Sworder, B. J., Stepan, L., Okal, A., Huang, C., Kang, X., Hamilton, J., Macaulay, C., Olsen, M., Liu, C., Diehn, M., Peiser, L., Kurtz, et al
ELSEVIER.2024: 3412
- **Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas**

- Kuehn, J. C., Md, R., Neidert, N. N., Mutter, J. A., Grabis, E., Alig, S. K., Zhang, J., Klingler, C., Bleul, S., Hummel, F., Ranganathan, L., Lauer, E. M., Heiland, et al
ELSEVIER.2024: 856-857
- **Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling**
Rossi, C., Boegeholz, J., Goldstein, J. S., Shi, S., Su, S., Tessoulin, B., Alig, S. K., Garofalo, A., Esfahani, M., Schroers-Martin, J. G., Liu, C., Olsen, M., Kang, et al
ELSEVIER.2024: 853-854
 - **Cell-Free DNA in Hematologic Malignancies.** *JCO oncology practice*
Schroers-Martin, J. G., Alizadeh, A. A.
2024; 20 (11): 1491-1499
 - **Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.** *Transplantation and cellular therapy*
Hamilton, M. P., Alizadeh, A. A.
2024; 30 (10): 936-938
 - **Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis**
Nanjo, S., Azad, T., Jin, M., Yano, S., Hui, A., Nagpal, S., Gephart, M. H., Alizadeh, A., Diehn, M.
ELSEVIER SCIENCE INC.2024: S478
 - **Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy REPLY** *NEW ENGLAND JOURNAL OF MEDICINE*
Hamilton, M. P., Miklos, D. B., Alizadeh, A. A.
2024; 391 (9): 870-871
 - **Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer.** *JCO precision oncology*
Murciano-Goroff, Y. R., Hui, A. B., Araujo Filho, J. A., Hamilton, E. G., Chabon, J. J., Moding, E. J., Bonilla, R. F., Lebow, E. S., Gomez, D., Rimner, A., Ginsberg, M. S., Offin, M., Kundra, et al
2024; 8: e2400216
 - **Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq**
Cabel, L., An, J., Kurtz, D., Ross, D., Dikoglu, E., Chen, Y., Murphy, K., Szuhany, K., Stowell, S., Maloney, D., Scher, H. I., Morrow, M., Robson, et al
ELSEVIER.2024: S338
 - **IKAROS mediates antigen escape following CD19-or CD22-targeted immunotherapies in r/r B-ALL**
Domizi, P., Sarno, J., Jager, A., Merchant, M., Pacheco, K., Yamada-Hunter, S., Rotiroti, M., Liu, Y., Baskar, R., Reynolds, W., Sworder, B., Sahaf, B., Bendall, et al
AMER ASSOC CANCER RESEARCH.2024
 - **Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Jun, S., Shukla, N. A., Durm, G., Hui, A. B., Cao, S., Ganti, A. K., Jabbour, S. K., Kunder, C., Alizadeh, A. A., Hanna, N. H., Diehn, M.
2024
 - **ViPOR's Venom - Rationally Targeting DLBCL with Precision.** *The New England journal of medicine*
Goldstein, J. S., Alizadeh, A. A.
2024; 390 (23): 2209-2211
 - **Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)**
Isbell, J. M., Goldstein, J., Hamilton, E. G., Liu, S., Eichholz, J., Buonocore, D. J., Rusch, V. W., Bott, M., Molena, D., Rocco, G., Yang, S., Rudin, C. M., Jones, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.** *NPJ precision oncology*
Azad, T. D., Nanjo, S., Jin, M. C., Chabon, J. J., Kurtz, D. M., Chaudhuri, A. A., Connolly, I. D., Hui, A. B., Liu, C. L., Merriott, D., Ko, R., Yoo, C., Carter, et al
2024; 8 (1): 121
 - **ULTRASENSITIVE URINARY LIQUID BIOPSY ANALYSIS FOR BCG RESPONSE ASSESSMENT IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER**

- Shi, W. Y., Liu, K. J., Esfahani, M. S., Schroers-Martin, J. G., Nesselbush, M., Chen, S. B., Alig, S. K., Mullane, P., Mach, K. E., Trabanino, L., Lee, T. J., Yoo, I., Vinh La, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: E1169
- **Predicting outcomes in locally advanced breast cancer through profiling post-neoadjuvant tissue-based minimal residual disease**
Ransohoff, J., Carleton, M., Birk, A., Bean, G., Telli, M., Alizadeh, A., Ford, J., Duran, G., Khodadoust, M., Kurtz, D.
AMER ASSOC CANCER RESEARCH.2024
 - **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
Hamilton, M. P., Craig, E., Gentile Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
2024
 - **Mathematical modeling of ctDNA dynamics to predict utility of ultrasensitive MRD assays in early stage non-small cell lung cancer (NSCLC)**
Goldstein, J. S., Abbosh, C., Alizadeh, A. A., Diehn, M., Kurtz, D. M.
AMER ASSOC CANCER RESEARCH.2024
 - **Highly accurate profiling of leukocyte composition from bulk peripheral blood with targeted digital cytometry**
Nakao, A., Newman, A. M., Alizadeh, A. A., Diehn, M., Ghosh, M., Aliminati, M., Ghosh, J., Stephenson, K., Ashutosh, A.
AMER ASSOC CANCER RESEARCH.2024
 - **Improved cfDNA methylation profiling through correction of misrepaired jagged-ends**
Wang, R., Hamilton, E. G., Almanza, D., Hui, A., Diehn, M., Alizadeh, A. A.
AMER ASSOC CANCER RESEARCH.2024
 - **A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.** *Cell stem cell*
Kastenschmidt, J. M., Schroers-Martin, J. G., Sworder, B. J., Sureshchandra, S., Khodadoust, M. S., Liu, C. L., Olsen, M., Kurtz, D. M., Diehn, M., Wagar, L. E., Alizadeh, A. A.
2024
 - **Specificity of Immunoglobulin High-Throughput Sequencing Minimal Residual Disease Monitoring in Non-Hodgkin Lymphomas.** *Blood advances*
Shukla, N., Schroers-Martin, J., Sworder, B., Kathuria, K. R., Alig, S., Frank, M. J., Miklos, D. B., Coutre, S. E., Diehn, M., Khodadoust, M. S., Roschewski, M. J., Kurtz, D. M., Alizadeh, et al
2023
 - **A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis.** *Blood advances*
Shree, T., Haebe, S. E., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L., Alizadeh, A. A., Advani, R. H., Hoppe, R. T., Long, et al
2023
 - **CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias**
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., Tamaresis, J., Esfahani, M., Lu, Y., Olsen, M., Liu, C., Ehlinger, Z., Desai, et al
AMER SOC HEMATOLOGY.2023
 - **Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study**
Sworder, B. J., Yoon, S., Kim, S., Schultz, A., Hogan, G., Close, S., Chabon, J. J., Diehn, M., Kurtz, D. M., Alizadeh, A. A., Kim, W.
AMER SOC HEMATOLOGY.2023
 - **Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma**
Kurtz, D. M., Hogan, G., Schultz, A., Chabon, J. J., Alizadeh, A. A., Havenith, K., Samari, S., Kopotsha, T., Wang, L., Qin, Y., Wang, Y., Pantano, S.
AMER SOC HEMATOLOGY.2023
 - **Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults**
Rossi, C., Boegeholz, J., Alig, S. K., Garofalo, A., Esfahani, M., Schroers-Martin, J., Olsen, M., Kang, X., Kurtz, D. M., Sugio, T., Hamilton, M. P., Andre, M., Casasnovas, et al
AMER SOC HEMATOLOGY.2023

- **Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification**
Mutter, J. A., Esfahani, M., Schroers-Martin, J., Alig, S. K., Hamilton, M. P., Sworder, B. J., Tessoulin, B., Boegeholz, J., Flerlage, T., Flerlage, J. E., Binkley, M. S., Sugio, T., Rossi, et al
AMER SOC HEMATOLOGY.2023
- **End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA**
Roschewski, M., Lindenberg, L., Mena, E., Lakhotia, R., Melani, C., Steinberg, S. M., Schultz, A., Hogan, G., Chabon, J. J., Close, S., Diehn, M., Sworder, B. J., Kurtz, et al
AMER SOC HEMATOLOGY.2023
- **An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring**
Sugio, T., Shukla, N., Khodadoust, M. S., Nesselbush, M., Kato, K., Alig, S. K., Boegeholz, J., Schroers-Martin, J., Esfahani, M., Mutter, J. A., Garofalo, A., Jun, S., Hamilton, et al
AMER SOC HEMATOLOGY.2023
- **Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas**
Nagy, A., Batai, B., Hogan, G., Chabon, J. J., Troke, M., Riley, L., Schultz, A., Close, S., Diehn, M., Alpar, D., Timar, B., Alizadeh, A. A., Kurtz, et al
AMER SOC HEMATOLOGY.2023
- **Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab plus AVD**
Lynch, R. C., Alig, S. K., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., Shadman, M., Till, B. G., Raghunathan, V., Tseng, Y. D., Ottemiller, S., Joy, B., Fessel, et al
AMER SOC HEMATOLOGY.2023
- **Investigating the Cell States and Prognostic Impact of Tumor Microenvironment Ecosystems in Classic Hodgkin Lymphoma**
Su, S., Subramanian, A., Flerlage, T., Flerlage, J. E., Alig, S. K., Moding, E. J., Hoppe, R. T., Advani, R. H., Natkunam, Y., Alizadeh, A. A., Binkley, M. S.
AMER SOC HEMATOLOGY.2023
- **Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods**
Alig, S. K., Esfahani, M., Garofalo, A., Li, M., Rossi, C., Flerlage, T., Flerlage, J. E., Adams, R., Binkley, M. S., Shukla, N., Jin, M., Olsen, M., Telenius, et al
AMER SOC HEMATOLOGY.2023
- **Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab plus AVD**
Lynch, R. C., Alig, S. K., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., Shadman, M., Till, B. G., Raghunathan, V., Tseng, Y. D., Ottemiller, S., Joy, B., Fessel, et al
AMER SOC HEMATOLOGY.2023
- **Investigating the Cell States and Prognostic Impact of Tumor Microenvironment Ecosystems in Classic Hodgkin Lymphoma**
Su, S., Subramanian, A., Flerlage, T., Flerlage, J. E., Alig, S. K., Moding, E. J., Hoppe, R. T., Advani, R. H., Natkunam, Y., Alizadeh, A. A., Binkley, M. S.
AMER SOC HEMATOLOGY.2023
- **Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods**
Alig, S. K., Esfahani, M., Garofalo, A., Li, M., Rossi, C., Flerlage, T., Flerlage, J. E., Adams, R., Binkley, M. S., Shukla, N., Jin, M., Olsen, M., Telenius, et al
AMER SOC HEMATOLOGY.2023
- **Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas. *Neuro-oncology***
Lauer, E. M., Riegler, E., Mutter, J. A., Alig, S. K., Bleul, S., Kuehn, J., Ranganathan, L., Klingler, C., Demerath, T., Wurtemberger, U., Rau, A., Weiss, J., Eisenblaetter, et al
2023
- **Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma. *Blood advances***
Spasevska, I., Sharma, A., Steen, C. B., Josefsson, S. E., Blaker, Y. N., Kolstad, A., Rustad, E. H., Meyer, S., Isaksen, K. T., Chellappa, S., Kushekhar, K., Beiske, K., Førsund, et al
2023

- **Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma.** *Annals of hematology*
Johansson, P., Alig, S., Richter, J., Hanoun, C., Rekowski, J., Durig, J., Ylstra, B., de Jong, D., Klapper, W., Alizadeh, A. A., Duhrsen, U., Huttmann, A.
2023
- **Identification and confirmation via in situ hybridization of Merkel cell polyomavirus in rare cases of posttransplant cutaneous T-cell lymphoma.** *Journal of cutaneous pathology*
Lawrence, L., Wang, A., Charville, G., Liu, C. L., Garofalo, A., Alizadeh, A., Jangam, D., Pinsky, B. A., Sahoo, M., Gratzinger, D., Khodadoust, M., Kim, Y., Novoa, et al
2023
- **17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.** *Hematological oncology*
Alig, S. K., Esfahani, M. S., Garofalo, A., Li, M. Y., Rossi, C., Adams, R., Binkley, M. S., Jin, M. C., Olsen, M., Telenius, A., Mutter, J., Sworder, B. J., Schroers-Martin, et al
2023; 41 Suppl 2: 96-98
- **17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.** *Hematological oncology*
Rossi, C., Boegeholz, J. L., Alig, S. K., Garofalo, A., Esfahani, M. S., Schroers-Martin, J., Olsen, M., Kang, X., Kurtz, D. M., Sugio, T., Hamilton, M. P., André, M., Casasnovas, et al
2023; 41 Suppl 2: 321-322
- **Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq**
Isbell, J. M., Li, B. T., Razavi, P., Reis-Filo, J., Liu, S., Selenica, P., Adusumilli, P., Bott, M., Jones, D. R., Rusch, V. W., Sihag, S., Buonocore, D. J., Jee, et al
AMER ASSOC CANCER RESEARCH.2023
- **RePhyNER: Overcoming limitations of access to matched germline for serial liquid biopsy applications**
Esfahani, M., Alig, S., Hamilton, E., Schroers-Martin, J., Sworder, B., Boegeholz, J., Olsen, M., Liu, C., Kurtz, D., Diehn, M., Alizadeh, A.
AMER ASSOC CANCER RESEARCH.2023
- **Improved cfDNA methylation profiling through correction of misrepaired jagged-ends**
Wang, R., Hamilton, E. G., Hui, A., Almanza, D., Esfahani, M. S., Diehn, M., Alizadeh, A. A.
AMER ASSOC CANCER RESEARCH.2023
- **Profiling Cellular Ecosystems at Single-Cell Resolution and at Scale with EcoTyper.** *Methods in molecular biology (Clifton, N.J.)*
Steen, C. B., Luca, B. A., Alizadeh, A. A., Gentles, A. J., Newman, A. M.
2023; 2629: 43-71
- **Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma.** *Blood*
Lynch, R. C., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., Shadman, M., Till, B. G., Raghunathan, V., Alig, S., Alizadeh, A. A., Gulhane, A., Chen, D., Tseng, et al
2023
- **Investigating and modeling positron emission tomography factors associated with large cell transformation from low-grade lymphomas.** *EJHaem*
Obeid, J. P., Hiniker, S. M., Schroers-Martin, J., Guo, H. H., No, H. J., Moding, E. J., Advani, R. H., Alizadeh, A. A., Hoppe, R. T., Binkley, M. S.
2023; 4 (1): 90-99
- **Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Mutter, J. A., Alig, S. K., Esfahani, M. S., Lauer, E. M., Mitschke, J., Kurtz, D. M., Kühn, J., Bleul, S., Olsen, M., Liu, C. L., Jin, M. C., Macaulay, C. W., Neidert, et al
2022: JCO2200826
- **Polatuzumab vedotin with infusional chemotherapy (Pola-DA-EPCH-R) for untreated aggressive B-cell non-Hodgkin lymphomas.** *Blood advances*
Lynch, R. C., Poh, C., Ujjani, C. S., Warren, E. H., Smith, S. D., Shadman, M., Morris, K., Lee, S., Rasmussen, H., Ottemiller, S., Shelby, M., Keo, S., Verni, et al

2022

- **Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS**
Shukla, N. D., Schroers-Martin, J., Kathuria, K. R., Sworder, B., Alig, S. K., Frank, M. J., Miklos, D. B., Coutre, S., Diehn, M., Khodadoust, M. S., Roschewski, M., Kurtz, D. M., Alizadeh, et al
AMER SOC HEMATOLOGY.2022: 6403-6404
- **Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study**
Mosquera, A., Hosoya, H., Jin, M. C., Esfahani, M., Schroers-Martin, J., Sworder, B., Liu, C., Spiteri, E., Natkunam, Y., Zehnder, J. L., Stehr, H., Kurtz, D. M., Alizadeh, et al
AMER SOC HEMATOLOGY.2022: 10712-10713
- **Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects**
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M., Good, Z., Sworder, B., Schroers-Martin, J., Liu, C., Severinsen, F., Hanson, P. J., Lu, Y., Lowsky, et al
AMER SOC HEMATOLOGY.2022: 7545-7547
- **Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma**
Greenwell, I., Switchenko, J. M., Craig, A. F. M., Alizadeh, A. A., Allen, P. B., Escobar, A., Valla, K., Abousaud, A., Parikh, P., Roberts, D., Neely, J. J., Palmer, A., Blum, et al
AMER SOC HEMATOLOGY.2022: 9373-9374
- **Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy**
Boegeholz, J., Alig, S. K., Sworder, B., Schroers-Martin, J., Macaulay, C., Craig, A. F. M., Duehrsen, U., Huettmann, A., Westin, J., Cherng, H. J., Miklos, D. B., Frank, M. J., Diehn, et al
AMER SOC HEMATOLOGY.2022: 8609-8610
- **Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders**
Schroers-Martin, J., Garofalo, A., Soo, J., Boegeholz, J., Alig, S. K., Sworder, B., Liu, C., Luikart, H., Gamino, G., Morales, D., Freystaetter, K., Hamilton, J., Kurtz, et al
AMER SOC HEMATOLOGY.2022
- **Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume**
Lynch, R. C., Alig, S. K., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., Shadman, M., Shustov, A., Till, B. G., Raghunathan, V., Tseng, Y. D., Coye, H., Shelby, et al
AMER SOC HEMATOLOGY.2022: 6547-6549
- **Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling**
Alig, S. K., Esfahani, M., Li, M. Y., Adams, R., Garofalo, A., Jin, M. C., Olsen, M., Telenius, A., Sworder, B., Schroers-Martin, J., King, D. A., Rossi, C., Schultz, et al
AMER SOC HEMATOLOGY.2022: 1295-1296
- **Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas**
Garofalo, A., Alig, S. K., Schroers-Martin, J., Shyam, R., Olsen, M., Kurtz, D. M., Rossi, C., Schultz, A., Kathuria, K. R., Liu, C., Spina, V., Flerlage, J. E., Castellino, et al
AMER SOC HEMATOLOGY.2022: 1318-1319
- **Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma**
Shree, T., Haebe, S., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L. S., Alizadeh, A. A., Advani, R. H., Hoppe, R., Long, et al
AMER SOC HEMATOLOGY.2022: 6450-6451
- **Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)**
Kurtz, D. M., Ahmed, S., Tong, C., Mei, M., Ding, C., Flinn, I. W., Riedell, P. A., Hogan, G. J., Schultz, A., Chabon, J. J., Heslop, H. E., Myo, A., Alizadeh, et al

AMER SOC HEMATOLOGY.2022: 2378-2380

- **MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design**
Roschewski, M., Kurtz, D. M., Westin, J., Lynch, R. C., Macaulay, C., Kuffer, C., Hogan, G. J., Close, S., Chabon, J. J., Rossi, D., Diehn, M., Alizadeh, A. A., Schultz, et al
AMER SOC HEMATOLOGY.2022
- **Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP**
Kurtz, D. M., Hogan, G. J., Schultz, A., Kopeckova, K., Kuffer, C., Blair, D., Wagner, S., Close, S., Diehn, M., Chabon, J. J., Alizadeh, A. A., Westin, J.
AMER SOC HEMATOLOGY.2022: 3498-3499
- **Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas**
Sworder, B., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N. D., Garofalo, A., Macaulay, C., Esfahani, M., Olsen, M., Hamilton, J., Hosoya, H., Hamilton, M. P., Spiegel, et al
AMER SOC HEMATOLOGY.2022: 1301-1303
- **A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. *Blood advances***
Cherng, H. J., Alig, S., Oki, Y., Nastoupil, L. J., Fayad, L. E., Neelapu, S. S., Turturro, F., Hagemester, F. B., Craig, A., Macaulay, C., Rodriguez, M. A., Lee, H. J., McDonnell, et al
2022
- **Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. *Cancer research***
Nair, V. S., Hui, A. B., Chabon, J. J., Shahrokh Esfahani, M., Stehr, H., Nabet, B. Y., Zhou, L., Chaudhuri, A. A., Benson, J. A., Ayers, K., Bedi, H., Ramsey, M. C., Van Wert, et al
2022
- **Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology***
Yang, L. M., Costales, C., Ramanathan, M., Bulterys, P. L., Murugesan, K., Schroers-Martin, J., Alizadeh, A. A., Boyd, S. D., Brown, J. M., Nadeau, K. C., Nadimpalli, S. S., Wang, A. X., Busque, et al
2022; 153: 105217
- **Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non-small cell lung cancer.**
Jun, S., Shukla, N., Durm, G., Hui, A. B., Cao, S., Kunder, C., Alizadeh, A. A., Hanna, N. H., Diehn, M.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.**
Cherng, H., Alig, S., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S., Turturro, F., Hagemester, F. B., Rodriguez, M., McDonnell, T., Flowers, C., Vega, F., Green, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. *Cancers***
Yaung, S. J., Woestmann, C., Ju, C., Ma, X. M., Gattam, S., Zhou, Y., Xi, L., Pal, S., Balasubramanyam, A., Tikoo, N., Heussel, C. P., Thomas, M., Kriegsmann, et al
2022; 14 (10)
- **CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity. *Blood cancer discovery***
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., Beygi, S., Kanegai, A. M., Corbelli, K. S., Gabriel, E., Kurtz, D. M., Khodadoust, M. S., Gupta, et al
2022
- **Circulating Tumor DNA in Lymphoma: Principles and Future Directions. *Blood cancer discovery***
Roschewski, M., Rossi, D., Kurtz, D. M., Alizadeh, A. A., Wilson, W. H.
1800; 3 (1): 5-15
- **Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis**
Schroers-Martin, J. G., Soo, J., Brisou, G., Scherer, F., Kurtz, D. M., Sworder, B., Khodadoust, M. S., Jin, M. C., Bru, A., Liu, C., Stehr, H., Vineis, P., Natkunam, et al

AMER SOC HEMATOLOGY.2021

- **Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma**
Spasevska, I., Sharma, A., Steen, C. B., Josefsson, S., Blaker, Y., Rustad, E. H., Meyer, S., Chellappa, S., Kushekhar, K., Kolstad, A., Beiske, K., Holte, H., Ostenstad, et al
AMER SOC HEMATOLOGY.2021
- **Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib**
Roschewski, M., Phelan, J. D., Pittaluga, S., Melani, C., Lakhota, R., Chabon, J. J., Muppidi, J. R., Lurain, K. A., Simard, J., Pradhan, A., Hillsman, A., Rilko, M., Steinberg, et al
AMER SOC HEMATOLOGY.2021
- **S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements**
Brem, E. A., Li, H., Beaven, A. W., Caimi, P. F., Cerchiatti, L., Alizadeh, A. A., Olin, R. L., Henry, N., Dillon, H., Little, R. F., Laubach, C., Leblanc, M. L., Friedberg, et al
AMER SOC HEMATOLOGY.2021
- **Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing**
Esfahani, M., Alig, S., Mehrmohamadi, M., Hamilton, E. G., King, D. A., Schultz, A., Steen, C. B., Macaulay, C., Sworder, B., Kurtz, D. M., Diehn, M., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2021
- **Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma**
Lynch, R. C., Ujjani, C. S., Poh, C., Warren, E. H., Smith, S. D., Shadman, M., Shustov, A. R., Till, B. G., Tseng, Y. D., Coye, H., Shelby, M., Ottemiller, S., Du, et al
AMER SOC HEMATOLOGY.2021
- **Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma**
Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., Advani, R., Maeda, L. S., Gupta, N. K., Khodadoust, M. S., Kurtz, D. M., Corbelli, K. S., Gabriel, et al
AMER SOC HEMATOLOGY.2021
- **SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. *Journal of geriatric oncology***
Brem, E. A., Li, H., Beaven, A. W., Caimi, P. F., Cerchiatti, L., Alizadeh, A. A., Olin, R., Henry, N. L., Dillon, H., Little, R. F., Laubach, C., LeBlanc, M., Friedberg, et al
2021
- **Circulating tumor DNA profiling for noninvasive detection, classification, and risk stratification of patients with CNS lymphomas**
Mutter, J. A., Alig, S., Lauer, E. M., Esfahani, M. S., Mitschke, J., Kurtz, D. M., Olsen, M., Liu, C. L., Jin, M. C., Bleul, S., Macaulay, C. W., Neidert, N. N., Heiland, et al
KARGER.2021: 90
- **A comprehensive circulating tumor DNA assay for detection of translocation and copy number changes in pediatric sarcomas. *Molecular cancer therapeutics***
Shah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H., Behroozfard, I. H., Wittber, F. M., Hazard, et al
2021
- **Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.**
Kurtz, D., Chabon, J. J., Sworder, B., Keh, L., Soo, J., Alig, S., Schultz, A., Garofalo, A., Hamilton, E. G., Chen, B., Olsen, M., Moding, E., Liu, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer.**
Moding, E., Hui, A. B., Murciano-Goroff, Y. R., Nabet, B., Schultz, A., Qiao, Y., Li, B. T., Lin, S. H., Alizadeh, A. A., Diehn, M.
LIPPINCOTT WILLIAMS & WILKINS.2021

- **Phased variants improve DLBCL minimal residual disease detection at the end of therapy.**
Kurtz, D., Chabon, J. J., Soo, J., Keh, L., Alig, S., Schultz, A., Jin, M. C., Scherer, F., Craig, A. F. M., Liu, C., Duehrsen, U., Huettmann, A., Casanovas, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., Yoo, C., Kurtz, D. M., Owen, S., Backhus, L. M., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER ASSOC CANCER RESEARCH.2021
- **Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.**
Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z., Das, M., Ramchandran, K. J., Padda, S. K., Neal, et al
AMER ASSOC CANCER RESEARCH.2021
- **Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.** *Cancer discovery*
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., Diehn, M.
2021
- **A mathematical model of ctDNA shedding predicts tumor detection size.** *Science advances*
Avanzini, S., Kurtz, D. M., Chabon, J. J., Moding, E. J., Hori, S. S., Gambhir, S. S., Alizadeh, A. A., Diehn, M., Reiter, J. G.
2020; 6 (50)
- **Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma**
Spasevska, I., Josefsson, S., Blaker, Y., Steen, C. B., Sharma, A., Kushekar, K., Meyer, S., Kolstad, A., Beiske, K., Holte, H., Ostenstad, B., Kimby, E., Olweus, et al
AMER SOC HEMATOLOGY.2020
- **CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucef but Can be Overcome through Novel CAR Engineering**
Majzner, R. G., Frank, M. J., Mount, C., Tousley, A., Kurtz, D. M., Sworder, B., Murphy, K. A., Manousopoulou, A., Kohler, K., Rotiroti, M., Spiegel, J. Y., Natkunam, Y., Younes, et al
AMER SOC HEMATOLOGY.2020
- **Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)**
Shukla, N. D., Craig, A. F. M., Sworder, B., Kurtz, D. M., Macaulay, C., Garofalo, A., Frank, M. J., Alig, S., Duran, G., Kim, Y. H., Zehnder, J., Mackall, C. L., Miklos, et al
AMER SOC HEMATOLOGY.2020
- **Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma**
Greenwell, I., Switchenko, J. M., Maddocks, K. J., Kahl, B. S., Craig, A. F. M., Alizadeh, A. A., Allen, P. B., Marbury, A., Escobar, A., Valla, K., Williams, M., Parikh, P., Roberts, et al
AMER SOC HEMATOLOGY.2020
- **Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage**
Schroers-Martin, J. G., Soo, J., Brisou, G., Scherer, F., Kurtz, D. M., Sworder, B., Khodadoust, M. S., Jin, M. C., Bru, A., Liu, C., Stehr, H., Vineis, P., Natkunam, et al
AMER SOC HEMATOLOGY.2020
- **A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer**
Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., Steen, C. B., Chaudhuri, A. A., Liu, C., Hui, A. B., Stehr, H., Goljenola, L., Jin, et al
AMER ASSOC CANCER RESEARCH.2020
- **Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors**
Luca, B. A., Steen, C. B., Azizi, A., Matusiak, M., Przybyl, J., Neishaboori, N., Perez, A., Diehn, M., Alizadeh, A. A., van de Rijn, M., Gentles, A. J., Newman, A. M.
AMER ASSOC CANCER RESEARCH.2020
- **Chromatin accessibility patterns in cell-free DNA reveal tumor heterogeneity**
Esfahani, M., Mehrmohamadi, M., Steen, C. B., Hamilton, E. G., King, D. A., Soo, J., Macaulay, C., Jin, M., Kurtz, D. M., Nabet, B., Moding, E., Chabon, J., Newman, et al

AMER ASSOC CANCER RESEARCH.2020

- **ctDNA shedding dynamics dictate early lung cancer detection potential**
Avanzini, S., Kurtz, D. M., Chabon, J. J., Hori, S. S., Alizadeh, A. A., Diehn, M., Reiter, J. G.
AMER ASSOC CANCER RESEARCH.2020: 25
- **Analytical validation of iSort digital cytometry for leukocyte enumeration in clinical tumor specimens.**
Newman, A. M., Nakao, A., Li, K., Wilson, D., Liu, C., Diehn, M., Alizadeh, A. A.
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Analytical validation of digital cytometry (iSort) for leukocyte enumeration using stored blood.**
Newman, A. M., Nakao, A., Li, K., Liu, C., Mathi, K., Sigal, N., Maecker, H., Diehn, M., Alizadeh, A. A.
AMER SOC CLINICAL ONCOLOGY.2020
- **A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.**
Moding, E. J., Esfahani, M., Nabet, B., Liu, Y., Chabon, J. J., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z. X., Das, M., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Early ctDNA response assessment for prediction of platinum sensitivity in small cell lung cancer.**
Murciano-Goroff, Y. R., Hui, A. B., Chabon, J. J., Moding, E. J., Lebow, E. S., Araujo-Filho, J. A., Isbell, J. M., Jones, D., Ginsberg, M. S., Myers, M. L., Offin, M., Drilon, A. E., Hellmann, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., Yoo, C., Kurtz, D., Owen, S., Backhus, L., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Next Generation Sequencing of Cerebrospinal Fluid to Improve Diagnostic Sensitivity, Detect Spatial Heterogeneity, and Predict Outcomes for Advanced Lung Cancer Patients with Leptomeningeal Carcinomatosis**
Azad, T., Nanjo, S., Chabon, J., Jin, M., Connolly, I., Ko, R., Yoo, C., Iv, M., Nagpal, S., Gephart, M., Alizadeh, A., Diehn, M.
AMER ASSOC NEUROLOGICAL SURGEONS.2020: 110
- **Circulating tumor DNA in Genetic Profiling and Monitoring of Pediatric Hodgkin Lymphoma**
Shyam, R., Kurtz, D., Alig, S., Jin, M., Link, M., Marks, L., Alizadeh, A.
GEORG THIEME VERLAG KG.2020: 81
- **Detection of circulating tumor DNA in pancreas cancer**
King, D., Alizadeh, A. A., Fisher, G. A.
AMER SOC CLINICAL ONCOLOGY.2020
- **Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. *Nature cancer***
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., Jones, C. D., He, J., Qiao, et al
2020; 1 (2): 176-183
- **Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. *Methods in molecular biology (Clifton, N.J.)***
Steen, C. B., Liu, C. L., Alizadeh, A. A., Newman, A. M.
2020; 2117: 135-57
- **Molecular and immunological signatures are related to clinical benefit from treatment with Vocimagene amiretrorepvec (Toca 511) and 5-fluorocytosine (Toca FC) in patients with glioma. *Clinical cancer research : an official journal of the American Association for Cancer Research***
Accomando, W. P., Rao, A. R., Hogan, D. J., Newman, A. M., Nakao, A. n., Alizadeh, A. A., Diehn, M. n., Diago, O. R., Gammon, D. K., Haghighi, A. n., Gruber, H. E., Jolly, D. J., Ostertag, et al
2020
- **Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. *Clinical cancer research : an official journal of the American Association for Cancer Research***
Hellmann, M. D., Nabet, B. Y., Rizvi, H. n., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P., Chabon, J. J., Liu, C. L., Hui, A. B., Arbour, K. C., Luo, J. n., Preeshagul, I. R., Moding, et al

2020

- **Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.** *Nature communications*
Wisdom, A. J., Mowery, Y. M., Hong, C. S., Himes, J. E., Nabet, B. Y., Qin, X. n., Zhang, D. n., Chen, L. n., Fradin, H. n., Patel, R. n., Bassil, A. M., Muise, E. S., King, et al
2020; 11 (1): 6410
- **Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.** *Blood advances*
Alig, S. n., Jurinovic, V. n., Shahrokh Esfahani, M. n., Haebe, S. n., Passerini, V. n., Hellmuth, J. C., Gaitzsch, E. n., Keay, W. n., Tahiri, N. n., Zoellner, A. n., Rosenwald, A. n., Klapper, W. n., Stein, et al
2020; 4 (18): 4451–62
- **KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.** *Cancer discovery*
Binkley, M. S., Jeon, Y. J., Nesselbush, M. n., Moding, E. J., Nabet, B. Y., Almanza, D. n., Kunder, C. n., Stehr, H. n., Yoo, C. H., Rhee, S. n., Xiang, M. n., Chabon, J. J., Hamilton, et al
2020
- **Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer** *NATURE CANCER*
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Gojenola, L., Jones, C. D., He, J., Qiao, Y., Heymach, et al
2020; 1: 176–183
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
- **Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.** *JAMA oncology*
Phillips, R. n., Shi, W. Y., Deek, M. n., Radwan, N. n., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C. n., Greco, S. C., Wang, H. n., Denmeade, et al
2020
- **An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma**
Steen, C. B., Luca, B. A., Esfahani, M., Nabet, B. Y., Sworder, B., Farshidfar, F., Shamardani, K., Kurtz, D. M., Liu, C., Advani, R. H., Natkunam, Y., Myklebust, J., Diehn, et al
AMER SOC HEMATOLOGY.2019
- **Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment**
Wagar, L. E., Sworder, B., Khodadoust, M. S., Davis, M. M., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2019
- **Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation**
Kathuria, K. R., Chen, B., Khodadoust, M. S., Olsson, N., Davis, M. M., Elias, J. E., Levy, R., Altman, R. B., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2019
- **Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies**
Garofalo, A., Schroers-Martin, J. G., Soo, J., Kurtz, D. M., Sworder, B., Liu, C., Pinsky, B. A., Luikart, H., Advani, R. H., Natkunam, Y., Khush, K., Diehn, M., Alizadeh, et al
AMER SOC HEMATOLOGY.2019
- **Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors**
Luca, B., Alizadeh, A., Diehn, M., Newman, A., Gentles, A., Steen, C.
BMC.2019
- **Broad Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer**
Nair, V., Hui, A., Chabon, J., Esfahani, M., Stehr, H., Nabet, B., Benson, J., Chaudhuri, A., Zhou, L., Ayers, K., Bedi, H., Ramsey, M., Van Wert, et al
ELSEVIER SCIENCE INC.2019: S747–S748

- **Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes**
Moding, E. J., Nabet, B. Y., Liu, Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Binkley, M. S., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, et al
ELSEVIER SCIENCE INC.2019: S113
- **Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.** *Science translational medicine*
Jain, N., Hartert, K., Tadros, S., Fiskus, W., Havranek, O., Ma, M. C., Bouska, A., Heavican, T., Kumar, D., Deng, Q., Moore, D., Pak, C., Liu, et al
2019; 11 (497)
- **ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.**
Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., He, J., Qiao, Y., Heymach, J., Tsao, A. S., Liao, Z. X., Gomez, D., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Early Detection of Post-Transplant Lymphoproliferative Disorder Using Circulating Tumor DNA**
Soo, J., Schroers-Martin, J., Garofalo, A., Kurtz, D., D'Emilio, N., Luikart, H., Alizadeh, A., Khush, K.
ELSEVIER SCIENCE INC.2019: S12–S13
- **Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply** *JOURNAL OF CLINICAL ONCOLOGY*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019; 37 (9): 755+
- **B-cell lymphomas present immunoglobulin neoantigens** *BLOOD*
Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B., Shree, T., Liu, C., Zhang, L., Czerwinski, D. K., Davis, M. M., Levy, R., Elias, J. E., Alizadeh, A. A.
2019; 133 (8): 878–81
- **Reply to J. Wang et al.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019: JCO1801907
- **Spatial mapping of the immune microenvironment in primary triple-negative breast cancer (TNBC) and association with neoadjuvant therapy response**
Telli, M. L., Vinayak, S., Khodadoust, M. S., Gruber, J. J., Ford, J. M., Sanchez, P., Banayan, N., Azimi, S., Tume, P. C., Newman, A. M., Alizadeh, A. A.
AMER ASSOC CANCER RESEARCH.2019
- **Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucef Therapy** *American Society of Hematology*
Sworder, B., Kurtz, D. M., Macaulay, C., Frank, M. J., Alig, S., Garofalo, A., Sahaf, B., Esfahani, M. S., Spiegel, J. Y., Oak, J., Beygi, S., Jin, M. C., Chabon, et al
2019
- **Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA** *American Society of Hematology*
Kurtz, D. M., Soo, J., Alig, S., Keh, L. C., Macaulay, C., Jin, M. C., Scherer, F., Hamilton, E. G., Liu, C., Chen, B., Craig, A., Diehn, M., Alizadeh, et al
2019
- **Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling** *American Society of Hematology*
Esfahani, M. S., Alig, S., Kurtz, D. M., Soo, J., Jin, M. C., Macaulay, C., Craig, A., Garofalo, A., Steen, C. B., Scherer, F., Sworder, B., Diehn, M., Alizadeh, et al
2019
- **Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer.** *Gastroenterology*
Azad, T. D., Chaudhuri, A. A., Fang, P. n., Qiao, Y. n., Esfahani, M. S., Chabon, J. J., Hamilton, E. G., Yang, Y. D., Lovejoy, A. n., Newman, A. M., Kurtz, D. M., Jin, M. n., Schroers-Martin, et al
2019
- **Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL** *American Society of Hematology*

- Macaulay, C., Alig, S., Kurtz, D. M., Jin, M. C., Opat, S., Soo, J., Sworder, B., Hertzberg, M. S., Gandhi, M. K., Diehn, M., Alizadeh, A. A.
2019
- **Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma** *American Society of Hematology*
Alig, S., Macaulay, C., Kurtz, D. M., Ulrich, D., Andreas, H., Jin, M. C., Sworder, B., Garofalo, A., Esfahani, M. S., Soo, J., Scherer, F., Craig, A., Casasnovas, et al
2019
 - **Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA** *American Society of Hematology*
Kurtz, D. M., Soo, J., Alig, S., Keh, L. C., Macaulay, C., Jin, M. C., Scherer, F., Hamilton, E. G., Liu, C., Chen, B., Craig, A., Diehn, M., Alizadeh, et al
2019
 - **Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling** *American Society of Hematology*
Esfahani, M. S., Alig, S., Kurtz, D. M., Soo, J., Jin, M. C., Macaulay, C., Craig, A., Garofalo, A., Steen, C. B., Scherer, F., Sworder, B., Diehn, M., Alizadeh, et al
2019
 - **Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing**
Schroers-Martin, J. G., Garofalo, A., Soo, J., Jin, M. C., Kurtz, D. M., Buedts, L., Duehrsen, U., Huettmann, A., Cottreau, A., Meignan, M., Casasnovas, O., Westin, J. R., Gaidano, et al
AMER SOC HEMATOLOGY.2018
 - **Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling**
Mehrmohamadi, M., Esfahani, M. S., Soo, J., Scherer, F., Schroers-Martin, J. G., Chen, B., Kurtz, D. M., Hamilton, E., Liu, C., Diehn, M., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2018
 - **Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma**
Jin, M. C., Schroers-Martin, J. G., Kurtz, D. M., Buedts, L., Esfahani, M. S., Macaulay, C., Sworder, B., Soo, J., Glover, C., Roschewski, M., Wilson, W. H., Duhrsen, U., Huettmann, et al
AMER SOC HEMATOLOGY.2018
 - **Analysis of Circulating Tumor DNA Kinetics during Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer**
Chen, E. L., Chaudhuri, A. A., Nabet, B. Y., Chabon, J. J., Merriott, D. J., Loo, B. W., Alizadeh, A. A., Diehn, M.
ELSEVIER SCIENCE INC.2018: E676
 - **Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst** *COLD SPRING HARBOR MOLECULAR CASE STUDIES*
Erdrich, J., Schaberg, K. B., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., Ford, J. M., Alizadeh, A. A., Quake, S. R., Kunz, P. L., Beausang, J. F.
2018; 4 (5)
 - **Quantitating circulating tumor DNA in translocation-positive sarcoma patients using CAPP-Seq**
Shah, A., Azad, T. D., Chabon, J. J., Breese, M., Tanasa, B., Spillinger, A., Leung, S. G., Diehn, M., Alizadeh, A. A., Sweet-Cordero, E.
AMER ASSOC CANCER RESEARCH.2018
 - **Circulating tumor DNA (ctDNA) in B-cell lymphoma**
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Green, M. R., Liu, C. L., Zhou, L., Glover, et al
WILEY.2018: 16–17
 - **Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst.** *Cold Spring Harbor molecular case studies*
Erdrich, J., Schaberg, K., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., Ford, J. M., Alizadeh, A. A., Quake, S. R., Kunz, P. L., Beausang, J. F.
2018
 - **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer**
Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., Newman, A. M., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H., Das, et al

ELSEVIER SCIENCE INC.2018: E1–E2

- **Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma** *CLINICAL CANCER RESEARCH*
Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K. N., Vennam, S., Newman, A. M., Forgo, E., Varma, S., Zhu, S., Debiec-Rychter, M., Alizadeh, A. A., Diehn, M., van de Rijn, et al
2018; 24 (11): 2688–99
- **Early detection of post-transplant lymphoproliferative disorder using circulating tumor DNA.**
Soo, J., Schroers-Martin, J., Garofalo, A., Kurtz, D., D'Emilio, N., Grimm, D.
AMER SOC CLINICAL ONCOLOGY.2018
- **Post-transplant head and neck cancers: A prospective analysis of clinical factors for risk stratification.**
Soo, J., Schroers-Martin, J., Garofalo, A., Kurtz, D., D'Emilio, N., Grimm, D.
AMER SOC CLINICAL ONCOLOGY.2018
- **Genomic Feature Selection by Coverage Design Optimization.** *Journal of applied statistics*
Reid, S., Newman, A. M., Diehn, M., Alizadeh, A. A., Tibshirani, R.
2018; 45 (14): 2658-2676
- **Circulating tumor DNA levels correlate with response to treatment in LMS patients**
Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K., Vennam, S., Newman, A. M., Forgo, E., Varma, S., Zhu, S., Debiec-Rychter, M., Alizadeh, A., Diehn, M., van de Rijn, et al
AMER ASSOC CANCER RESEARCH.2018: 38–39
- **Detection and surveillance of bladder cancer using urine tumor DNA.** *Cancer discovery*
Dudley, J. C., Schroers-Martin, J. n., Lazzareschi, D. V., Shi, W. Y., Chen, S. B., Esfahani, M. S., Trivedi, D. n., Chabon, J. J., Chaudhuri, A. A., Stehr, H. n., Liu, C. L., Lim, H. n., Costa, et al
2018
- **Genomic Profiling of Bronchoalveolar Lavage Fluid in Patients with Non-Small Cell Lung Cancer**
Nair, V. S., Li, A., Stehr, H., Chabon, J., Chaudhuri, A., Zhou, L., Naemi, H., Ayers, K., Ramsey, M., Bedi, H. S., Van Wert, R., Sung, A. W., Lui, et al
AMER THORACIC SOC.2018
- **Genomic feature selection by coverage design optimization** *Journal of Applied Statistics*
Reid, S., Newman, A. M., Diehn, M., Alizadeh, A. A., Tibshirani, R.
2018
- **Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Przybyl, J. n., Chabon, J. J., Spans, L. n., Ganjoo, K. n., Vennam, S. n., Newman, A. M., Forgó, E. n., Varma, S. n., Zhu, S. n., Debiec-Rychter, M. n., Alizadeh, A. A., Diehn, M. n., van de Rijn, et al
2018
- **Profiling Tumor Infiltrating Immune Cells with CIBERSORT.** *Methods in molecular biology (Clifton, N.J.)*
Chen, B. n., Khodadoust, M. S., Liu, C. L., Newman, A. M., Alizadeh, A. A.
2018; 1711: 243–59
- **Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma**
Kurtz, D. M., Scherer, F., Jin, M., Soo, J., Craig, A., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
AMER SOC HEMATOLOGY.2017
- **Maria: Accurate Prediction of MHC-II Peptide Presentation with Deep-Learning and Lymphoma Patient MHC-II Ligandome**
Chen, B., Khodadoust, M., Olsson, N., Fast, E., Wagar, L. E., Liu, C., Davis, M., Levy, R., Elias, J. E., Altman, R. B., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2017
- **Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis**
Schroers-Martin, J. G., Scherer, F., Soo, J., Kurtz, D. M., Liu, C., Stehr, H., Bru, A., Natkunam, Y., Diehn, M., Nadel, B., Roulland, S., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2017

- **Clinical Impact of Somatic Copy Number Alterations in Circulating Tumor DNA from Diverse Lymphoma Subtypes**
Jin, M., Kurtz, D. M., Esfahani, M. S., Soo, J., Craig, A., Scherer, F., Stehr, H., Schroers-Martin, J. G., Bangs, C., Cherry, A., Natkunam, Y., Roschewski, M., Wilson, et al
AMER SOC HEMATOLOGY.2017
- **Reproducibility of m7-FLIPI Risk Scores in Follicular Lymphoma Using Tumor Biopsies and Blood Specimens**
Soo, J., Scherer, F., Kurtz, D. M., Schroers-Martin, J. G., Jin, M., Craig, A., Stehr, H., Liu, C., Green, M. R., Weigert, O., Diehn, M., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2017
- **Comparison of Circulating Tumor DNA Recovery from Plasma and Serum**
Soo, J., Kurtz, D. M., Jin, M., Scherer, F., Schroers-Martin, J. G., Esfahani, M. S., Craig, A., Stehr, H., Neelapu, S. S., Nastoupil, L., Roschewski, M., Wilson, W. H., Diehn, et al
AMER SOC HEMATOLOGY.2017
- **Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes**
Schroers-Martin, J. G., Kurtz, D. M., Soo, J., Jin, M., Scherer, F., Craig, A., Chabon, J. J., Liu, C., Stehr, H., Duehrsen, U., Huttmann, A., Cottreau, A., Meignan, et al
AMER SOC HEMATOLOGY.2017
- **Circulating Tumor DNA Is a Reliable Measure of Tumor Burden at Diagnosis of Diffuse Large B Cell Lymphoma: An International Reproducibility Study**
Kurtz, D. M., Jin, M., Soo, J., Scherer, F., Craig, A., Chabon, J. J., Schroers-Martin, J. G., Liu, C., Stehr, H., Schmitz, C., Duehrsen, U., Huttmann, A., Cottreau, et al
AMER SOC HEMATOLOGY.2017
- **KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Kunder, C. A., Roncador, G., Advani, R. H., Gualco, G., Bacchi, C. E., Sabile, J. M., Lossos, I. S., Nie, K., Tibshirani, R., Green, M. R., Alizadeh, A. A., Natkunam, Y.
2017; 148 (6): 465–76
- **Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA**
Chabon, J., Chaudhuri, A., Azad, T., Kurtz, D., Stehr, H., Liu, C. L., Martin, J., Merriott, D., Carter, J., Ayers, K., Mansfield, A., Jen, J., Ren, et al
ELSEVIER SCIENCE INC.2017: S1851
- **Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer**
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., Carter, J. N., Merriott, D. J., Liu, C. L., Kurtz, D. M., Gensheimer, M. F., Shrager, J. B., Wakelee, et al
ELSEVIER SCIENCE INC.2017: S114
- **Pretreatment Circulating Tumor DNA for Risk Stratification of Locally Advanced Esophageal Cancer Treated With Chemoradiation and Surgery**
Azad, T. D., Chaudhuri, A. A., Newman, A., Stehr, H., Schroers-Martin, J., Chabon, J. J., Fang, P., Qiao, Y., Liao, Z., Komaki, R. U., Alizadeh, A. A., Lin, S. H., Diehn, et al
ELSEVIER SCIENCE INC.2017: S90–S91
- **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer**
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H. R., Das, M., Padda, S., Loo, et al
ELSEVIER SCIENCE INC.2017: S20–S21
- **Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome**
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Merriott, D. J., Carter, J. N., Azad, T. D., Padda, S., Gensheimer, M. F., Wakelee, H. A., Neal, J. W., Loo, et al
ELSEVIER SCIENCE INC.2017: S1–S2
- **On the hunt for cancer neoantigens: is mass spectrometry the solution?**
Elias, J., Olsson, N., Khodadoust, M., Wagar, L., Swaminathan, K., Green, M. R., Davis, M. M., Levy, R., Alizadeh, A. A.
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC.2017: S65
- **Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance**
Jeong, Y., Ngoc Hoang, Stehr, H., Lovejoy, A., Gentles, A., Chaudhuri, A., Loo, B., Alizadeh, A., Diehn, M.

AMER ASSOC CANCER RESEARCH.2017

- **Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging**
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Zhou, L., Liu, C., Scherer, F., Kurtz, D. M., Esfahani, M. S., Say, C., Carter, et al
ELSEVIER SCIENCE INC.2017: E4
- **Circulating tumor DNA analysis for outcome prediction in localized esophageal cancer.**
Azad, T. D., Chaudhuri, A., Newman, A. M., Stehr, H., Schroers-Martin, J., Chabon, J. J., Fang, P., Qiao, Y., Liao, Z. X., Komaki, R., Alizadeh, A. A., Lin, S. H., Diehn, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA).**
Diehn, M., Alizadeh, A. A., Adams, H., Lee, J. J., Klassen, S., Palma, J. F., Hinzman, B., Lovejoy, A. F., Newman, A. M., Yao, L., Yang, S., Balasubramanyam, A., Rohr, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies.**
Chaudhuri, A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Carter, J. N., Merriott, D. J., Liu, C., Kurtz, D., Dudley, J. C., Padda, S., Shrager, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA.**
Soo, J., Kurtz, D., Scherer, F., Craig, A. F. M., Jin, M. C., Westin, J. R., Rossi, D., Gaidano, G., Advani, R. H., Diehn, M., Alizadeh, A. A.
AMER SOC CLINICAL ONCOLOGY.2017
- **Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.**
Jin, M. C., Kurtz, D., Esfahani, M., Scherer, F., Craig, A. F. M., Soo, J., Khodadoust, M., Saganty, R., Chabon, J. J., Schroers-Martin, J., Stehr, H., Advani, R. H., Rossi, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **overexpression to promote lymphoma in mice. *Blood***
García-Ramírez, I., Tadros, S., González-Herrero, I., Martín-Lorenzo, A., Rodríguez-Hernández, G., Moore, D., Ruiz-Roca, L., Blanco, O., Alonso-López, D., Rivas, J. D., Hartert, K., Duval, R., Klinkebiel, et al
2017; 129 (19): 2645-2656
- **Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice *BLOOD***
Garcia-Ramirez, I., Tadros, S., Gonzalez-Herrero, I., Martin-Lorenzo, A., Rodriguez-Hernandez, G., Moore, D., Ruiz-Roca, L., Blanco, O., Alonso-Lopez, D., De Las Rivas, J., Hartert, K., Duval, R., Klinkebiel, et al
2017; 129 (19): 2645-2656
- **Antigen presentation profiling reveals T-cell recognition of lymphoma immunoglobulin neoantigens**
Olsson, N., Khodadoust, M., Wagar, L., Swaminathan, K., Haabeth, O., Chen, B., Rawson, K., Liu, C., Steiner, D., Lund, P. J., Rao, S., Zhang, L., Marceau, et al
AMER ASSOC IMMUNOLOGISTS.2017
- **Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens *NATURE***
Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A., Chen, B., Swaminathan, K., Rawson, K., Liu, C. L., Steiner, D., Lund, P., Rao, S., Zhang, L., Marceau, et al
2017; 543 (7647): 723-?
- **Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. *Blood***
Myklebust, J. H., Brody, J., Kohrt, H. E., Kolstad, A., Czerwinski, D. K., Wälchli, S., Green, M. R., Trøen, G., Liestøl, K., Beiske, K., Houot, R., Delabie, J., Alizadeh, et al
2017; 129 (6): 759-770
- **Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance *CANCER DISCOVERY***
Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., Kong, W., Diana Truong, D., Martin, S., Chaudhuri, A., Heiser, D., Zhou, L., Say, et al

2017; 7 (1): 86-101

- **Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer**
Chaudhuri, A., Lovejoy, A., Chabon, J., Newman, A., Stehr, H., Say, C., Carter, J., Zhou, L., West, R., Shrager, J., Neal, J., Wakelee, H., Loo, et al
ELSEVIER SCIENCE INC.2017: S445
- **Data normalization considerations for digital tumor dissection.** *Genome biology*
Newman, A. M., Gentles, A. J., Liu, C. L., Diehn, M. n., Alizadeh, A. A.
2017; 18 (1): 128
- **High-throughput sequencing for noninvasive disease detection in hematologic malignancies.** *Blood*
Scherer, F. n., Kurtz, D. M., Diehn, M. n., Alizadeh, A. A.
2017; 130 (4): 440–52
- **Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.** *Cancer discovery*
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H. n., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L. n., Scherer, F. n., Kurtz, D. M., Say, et al
2017
- **Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA**
Scherer, F., Kurtz, D. M., Newman, A. M., Craig, A., Stehr, H., Zhou, L., Glover, C., Kohrt, H., Levy, R., Diehn, M., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2016
- **Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study**
Khodadoust, M., Rook, A. H., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., Shanbhag, S., Sokol, L., Shine, R., Fling, S. P., Li, S., Rabhar, Z., Kim, et al
AMER SOC HEMATOLOGY.2016
- **Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma**
Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., Chabon, J. J., Esfahani, M., Liu, C., Zhou, L., Glover, C., Visser, B. C., Poultsides, et al
AMER SOC HEMATOLOGY.2016
- **Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations**
Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C., Zhou, L., Glover, C., Advani, R. H., Maeda, L. S., Gupta, N. K., Levy, R., Kunder, et al
AMER SOC HEMATOLOGY.2016
- **Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma** *58th Annual Meeting and Exposition of the American-Society-of-Hematology*
Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., Lovejoy, A. F., Chabon, J. J., Liu, C. L., Zhou, L., Glover, C., Visser, B. C., Poultsides, et al
AMER SOC HEMATOLOGY.2016
- **DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma**
Hartert, K., Tadros, S., Bouska, A., Moore, D., Pak, C., Heavican, T., Liu, C., Gentles, A. J., Hartmann, E. M., Kridel, R., Smedby, K., Juliusson, G., Rosenquist, et al
AMER SOC HEMATOLOGY.2016
- **Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens**
Khodadoust, M., Olsson, N., Wagar, L., Chen, B., Rawson, K., Liu, C., Steiner, D., Rao, S., Zhang, L., Stehr, H., Newman, A. M., Czerwinski, D. K., Carlton, et al
AMER SOC HEMATOLOGY.2016
- **CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer**
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Say, C., Aggarwal, S., Carter, J. N., West, R. B., Neal, J. W., Wakelee, H. A., Loo, B. W., Alizadeh, et al
ELSEVIER SCIENCE INC.2016: S41–S42
- **A phase 2 study of glebatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma**

- Ott, P. A., Pavlick, A. C., Johnson, D. B., Hart, L. L., Infante, J. R., Luke, J. J., Lutzky, J., Rothschild, N., Spittle, L., Cowey, C. L., Alizadeh, A., Salama, A., He, et al
OXFORD UNIV PRESS.2016
- **Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.** *Cancer discovery*
Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., Kong, W., Truong, D., Martin, S., Chaudhuri, A., Heiser, D., Zhou, L., Say, et al
2016
 - **High-throughput genomic profiling of tumor-infiltrating leukocytes.** *Current opinion in immunology*
Newman, A. M., Alizadeh, A. A.
2016; 41: 77-84
 - **Noninvasive molecular subtyping and risk stratification of DLBCL.**
Scherer, F., Kurtz, D., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C., Zhou, L., Glover, C., Advani, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.**
Kurtz, D., Scherer, F., Newman, A. M., Craig, A. F. M., Khodadoust, M., Lovejoy, A. F., Klass, D. M., Chabon, J. J., Glover, C., Zhou, L., Liu, C., Gupta, N. K., Maeda, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.**
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D., Chabon, J. J., Scherer, F., Stehr, H., Liu, C., Bratman, S., Say, C., Zhou, L., Carter, J. N., West, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.**
Chabon, J., Simmons, A., Newman, A. M., Lovejoy, A. F., Esfahani, M. S., Haringsma, H., Kurtz, D., Stehr, H., Scherer, F., Durkin, K. A., Otterson, G., Purcell, W. T., Camidge, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Tumor Lesion Glycolysis as an Indicator of Prognosis in the pre-treatment Phase of Patients with DLBCL**
Flynt, L., Quon, A., Alizadeh, A., Kurtz, D.
SOC NUCLEAR MEDICINE INC.2016
 - **Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA**
Esfahani, M., Newman, A. M., Scherer, F., Tibshirani, R., Diehn, M., Alizadeh, A. A., ACM
ASSOC COMPUTING MACHINERY.2016: 516
 - **Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma**
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C., Zhou, L., Craig, A. F. M., Chabon, J. J., Lovejoy, A. F., Klass, D. M., Glover, C., Ohgami, R. S., Kunder, et al
AMER SOC HEMATOLOGY.2015
 - **Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma**
Kurtz, D. M., Scherer, F., Newman, A. M., Lovejoy, A. F., Klass, D. M., Chabon, J. J., Gambhir, S., Diehn, M., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2015
 - **Organocatalytic removal of formaldehyde adducts from RNA and DNA bases (vol 7, pg 752, 2015) NATURE CHEMISTRY**
Karmakar, S., Harcourt, E. M., Hewings, D. S., Scherer, F., Lovejoy, A. F., Kurtz, D. M., Ehrenschwender, T., Barandun, L. J., Roost, C., Alizadeh, A. A., Kool, E. T.
2015; 7 (12): 1033
 - **The prognostic landscape of genes and infiltrating immune cells across human cancers**
Gentles, A. J., Newman, A. M., Liu, C., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Yue, X., Khuong, A., Hoang, C. D., Diehn, M., West, R. B., Plevritis, et al
AMER ASSOC CANCER RESEARCH.2015
 - **The VarScan2's SNVs-Near-Indel Filter: Is It Necessary?**

Suarez, C. J., Stehr, H., Fung, E., Kunder, C. A., Ewalt, M. D., Lal, A., Alizadeh, A., Diehn, M., Schrijver, I., Zehnder, J.
ELSEVIER SCIENCE INC.2015: 801

- **Analysis of Circulating Tumor DNA in Esophageal Carcinoma Patients Treated With Chemoradiation Therapy**
Klass, D., Newman, A., Lovejoy, A. F., Zhou, L., Stehr, H., Xu, T., He, J., Komaki, R. U., Liao, Z., Maru, D., Alizadeh, A., Lin, S. H., Diehn, et al
ELSEVIER SCIENCE INC.2015: S104–S105
- **Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.** *Seminars in radiation oncology*
Chaudhuri, A. A., Binkley, M. S., Osmundson, E. C., Alizadeh, A. A., Diehn, M.
2015; 25 (4): 305-312
- **Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.** *Journal of the National Cancer Institute*
Gentles, A. J., Bratman, S. V., Lee, L. J., Harris, J. P., Feng, W., Nair, R. V., Shultz, D. B., Nair, V. S., Hoang, C. D., West, R. B., Plevritis, S. K., Alizadeh, A. A., Diehn, et al
2015; 107 (10)
- **Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.** *Journal of the National Cancer Institute*
Gentles, A. J., Bratman, S. V., Lee, L. J., Harris, J. P., Feng, W., Nair, R. V., Shultz, D. B., Nair, V. S., Hoang, C. D., West, R. B., Plevritis, S. K., Alizadeh, A. A., Diehn, et al
2015; 107 (10)
- **Organocatalytic removal of formaldehyde adducts from RNA and DNA bases** *NATURE CHEMISTRY*
Karmakar, S., Harcourt, E. M., Hewings, D. S., Lovejoy, A. F., Kurtz, D. M., Ehrenschwender, T., Barandun, L. J., Roost, C., Alizadeh, A. A., Kool, E. T.
2015; 7 (9): 752-758
- **Organocatalytic removal of formaldehyde adducts from RNA and DNA bases.** *Nature chemistry*
Karmakar, S., Harcourt, E. M., Hewings, D. S., Scherer, F., Lovejoy, A. F., Kurtz, D. M., Ehrenschwender, T., Barandun, L. J., Roost, C., Alizadeh, A. A., Kool, E. T.
2015; 7 (9): 752-758
- **Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging** *PLOS ONE*
Whiting, C. C., Siebert, J., Newman, A. M., Du, H., Alizadeh, A. A., Goronzy, J., Weyand, C. M., Krishnan, E., Fathman, C. G., Maecker, H. T.
2015; 10 (7)
- **Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.**
Kurtz, D., Scherer, F., Green, M., Khodadoust, M., Klass, D. M., Zhou, L., Krishnan, R., Glover, C., Liu, C., Kong, K. A., Faham, M., Levy, R., Diehn, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)**
Scherer, F., Kurtz, D., Green, M., Newman, A. M., Klass, D. M., Zhou, L., Krishnan, R., Liu, C., Glover, C., Ohgami, R. S., Hicks, R. J., Keane, C., Kong, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **Deconvoluting immune cell populations using 'in silico flow cytometry' with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC**
Vinayak, S., Newman, A., Adams, S., Afghahi, A., Jensen, K. C., Badve, S. S., Ford, J. M., Alizadeh, A. A., Telli, M. L.
AMER ASSOC CANCER RESEARCH.2015
- **Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.** *Expert review of molecular diagnostics*
Bratman, S. V., Newman, A. M., Alizadeh, A. A., Diehn, M. n.
2015: 1–5
- **Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging.** *PLoS one*
Whiting, C. C., Siebert, J., Newman, A. M., Du, H., Alizadeh, A. A., Goronzy, J., Weyand, C. M., Krishnan, E., Fathman, C. G., Maecker, H. T.
2015; 10 (7)
- **A Simple Method for Estimating Interactions Between a Treatment and a Large Number of Covariates** *JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION*

- Tian, L., Alizadeh, A. A., Gentles, A. J., Tibshirani, R.
2014; 109 (508): 1517-1532
- **Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., Arber, D. A.
2014; 142 (6): 803-808
 - **Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., Arber, D. A.
2014; 142 (6): 803-808
 - **Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing**
Diehn, M., Bratman, S. V., Newman, A. M., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, A.
ELSEVIER SCIENCE INC.2014: S75
 - **A Simple Method for Estimating Interactions between a Treatment and a Large Number of Covariates.** *Journal of the American Statistical Association*
Tian, L., Alizadeh, A. A., Gentles, A. J., Tibshirani, R.
2014; 109 (508): 1517-1532
 - **Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC**
Modlin, L. A., Bratman, S. V., Newman, A. M., Eclow, N. W., Neal, J. W., Wakelee, H. A., Shrager, J. B., Loo, B. W., Alizadeh, A. A., Diehn, M.
ELSEVIER SCIENCE INC.2014: S812
 - **Circulating Tumor DNA as a Biomarker for Pancreatic Adenocarcinoma**
Osmundson, E., Newman, A. M., Bratman, S. V., Klass, D. M., Zhou, L., Pai, J., Longacre, T. A., Alizadeh, A. A., Koong, A. C., Diehn, M.
ELSEVIER SCIENCE INC.2014: S816–S817
 - **Common progenitor cells in mature B-cell malignancies: implications for therapy.** *Current opinion in hematology*
Green, M. R., Alizadeh, A. A.
2014; 21 (4): 333-340
 - **Common progenitor cells in mature B-cell malignancies: implications for therapy** *CURRENT OPINION IN HEMATOLOGY*
Green, M. R., Alizadeh, A. A.
2014; 21 (4): 333-340
 - **Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.** *Journal of clinical oncology*
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timmerman, et al
2014; 32 (17): 1797-1803
 - **Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.**
Kurtz, D., Green, M. R., Bratman, S., Liu, C., Glover, C., Keane, C., Kong, K., Faham, M., Miklos, D., Advani, R. H., Levy, R., Hertzberg, M. S., Gandhi, et al
AMER SOC CLINICAL ONCOLOGY.2014
 - **Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.**
Bratman, S., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H. A., Shrager, J. B., Loo, B. W., Diehn, M., Alizadeh, A. A.
AMER SOC CLINICAL ONCOLOGY.2014
 - **Tumor antigen discovery through translation of the cancer genome.** *Immunologic research*
Khodadoust, M. S., Alizadeh, A. A.
2014; 58 (2-3): 292-299
 - **Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.** *Nature communications*
Green, M. R., Vicente-Dueñas, C., Romero-Camarero, I., Long Liu, C., Dai, B., González-Herrero, I., García-Ramírez, I., Alonso-Escudero, E., Iqbal, J., Chan, W. C., Campos-Sanchez, E., Orfao, A., Pintado, et al
2014; 5: 3904-?

- **Hit-and-run lymphomagenesis by the Bcl6 oncogene.** *Cell cycle*
Green, M. R., Vicente-Dueñas, C., Alizadeh, A. A., Sánchez-García, I.
2014; 13 (12): 1831-1832
- **Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM**
Myklebust, J., Brody, J., Alizadeh, A. A., Czerwinski, D. K., Kolstad, A., Green, M. R., Houot, R., Delabie, J., Kohrt, H. E., Irish, J. M., Levy, R.
AMER SOC HEMATOLOGY.2013
- **Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing**
Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H., Shrager, J., Loo, B. W., Alizadeh, A. A., Diehn, M.
ELSEVIER SCIENCE INC.2013: S92
- **Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy** *SURGICAL ONCOLOGY-OXFORD*
Yang, J., Du, X.
2013; 22 (3): E53-E57
- **Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation.** *Clinical immunology*
Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Tibshirani, R. J., Strober, S., Sarwal, M., Lowsky, R.
2013; 148 (1): 124-135
- **Utility in prognostic value added by molecular profiles for diffuse large B-cell lymphoma.** *Blood*
Gentles, A. J., Alizadeh, A. A.
2013; 121 (15): 3052-3054
- **Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study.** *Leukemia & lymphoma*
Keegan, T. H., Moy, L. M., Foran, J. M., Alizadeh, A. A., Chang, E. T., Shema, S. J., Schupp, C. W., Clarke, C. A., Glaser, S. L.
2013; 54 (4): 743-751
- **Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study** *LEUKEMIA & LYMPHOMA*
Keegan, T. H., Moy, L. M., Foran, J. M., Alizadeh, A. A., Chang, E. T., Shema, S. J., Schupp, C. W., Clarke, C. A., Glaser, S. L.
2013; 54 (4): 743-751
- **High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.** *Blood*
Myklebust, J. H., Irish, J. M., Brody, J., Czerwinski, D. K., Houot, R., Kohrt, H. E., Timmerman, J., Said, J., Green, M. R., Delabie, J., Kolstad, A., Alizadeh, A. A., Levy, et al
2013; 121 (8): 1367-1376
- **Characterization of the Novel Germinal Center Marker KLHL6 in Human Lymphomas**
Kunder, C. A., Zhao, S., Martinez, E. G., Roncador, G., Alizadeh, A. A., Lossos, I. S., Natkunam, Y.
NATURE PUBLISHING GROUP.2013: 338A-339A
- **Characterization of the Novel Germinal Center Marker KLHL6 in Human Lymphomas**
Kunder, C. A., Zhao, S., Martinez, E. G., Roncador, G., Alizadeh, A. A., Lossos, I. S., Natkunam, Y.
NATURE PUBLISHING GROUP.2013: 338A-339A
- **Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation.** *Nature communications*
Romero-Camarero, I., Jiang, X., Natkunam, Y., Lu, X., Vicente-Dueñas, C., Gonzalez-Herrero, I., Flores, T., Garcia, J. L., McNamara, G., Kunder, C., Zhao, S., Segura, V., Fontan, et al
2013; 4: 1338-?
- **The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses.**
Pachynski, R., Zabel, B., Monnier, J., Gentles, A., Swanson, C., Kohrt, H., Hadeiba, H., Alizadeh, A., Butcher, E.
AMER ASSOC CANCER RESEARCH.2013
- **Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation** *NATURE COMMUNICATIONS*
Romero-Camarero, I., Jiang, X., Natkunam, Y., Lu, X., Vicente-Duenas, C., Gonzalez-Herrero, I., Flores, T., Luis Garcia, J., McNamara, G., Kunder, C., Zhao, S., Segura, V., Fontan, et al

2013; 4

- **Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Levy, R., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2012
- **Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation**
Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Strober, S., Sarwal, M., Lowsky, R.
AMER SOC HEMATOLOGY.2012
- **The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Coutinho, R., Newman, A. M., Rossignoli, G., Day, W., Miraki-Moud, F., Chaplin, T., Marzec, J., Petty, R. D., Iqbal, S., Matthews, J., Alizadeh, A. A., Gribben, J. G.
AMER SOC HEMATOLOGY.2012
- **Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell Signatures Related to Survival** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Newman, A. M., Gentles, A. J., Plevritis, S. K., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2012
- **Genome-Wide Characterization of Human Hematopoietic Progenitor Cell Heterogeneity by Expression Profiling of Single Cells: A Pilot Study** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Liu, C. L., Dai, B., Newman, A. M., Majeti, R., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2012
- **Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Strober, S., Sarwal, M., Lowsky, R.
AMER SOC HEMATOLOGY.2012
- **Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Torchia, J. A., Ng, P. P., Chen, H., Kohrt, H. E., Marabelle, A., Alizadeh, A. A., Levy, R.
AMER SOC HEMATOLOGY.2012
- **Self-antigen recognition by follicular lymphoma B-cell receptors** *BLOOD*
Sachen, K. L., Strohman, M. J., Singletary, J., Alizadeh, A. A., Kattah, N. H., Lossos, C., Mellins, E. D., Levy, S., Levy, R.
2012; 120 (20): 4182-4190
- **Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer** *54th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Bratman, S. V., Eclov, N. C., Modlin, L. A., Neal, J., Loo, B. W., Wu, G., Richardson, K., Newman, A. M., Alizadeh, A., Diehn, M.
ELSEVIER SCIENCE INC.2012: S713-S713
- **Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma** *PLOS ONE*
Huse, K., Bakkebo, M., Walchli, S., Oksvold, M. P., Hilden, V. I., Forfang, L., Bredahl, M. L., Liestol, K., Alizadeh, A. A., Smeland, E. B., Myklebust, J. H.
2012; 7 (10)
- **Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., Bates, J., Sekeres, M. A., Coutre, S., Kalaycio, M., Sobecks, R., Copelan, E., Advani, et al
2012; 87 (10): 957-960
- **CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas Diagnostic and Therapeutic Implications** *AMERICAN JOURNAL OF PATHOLOGY*

- Anderson, M. W., Zhao, S., Freud, A. G., Czerwinski, D. K., Kohrt, H., Alizadeh, A. A., Houot, R., Azambuja, D., Biasoli, I., Morais, J. C., Spector, N., Molina-Kirsch, H. F., Warnke, et al
2012; 181 (3): 795-803
- **The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses** *JOURNAL OF EXPERIMENTAL MEDICINE*
Pachynski, R. K., Zabel, B. A., Kohrt, H. E., Tejada, N. M., Monnier, J., Swanson, C. D., Holzer, A. K., Gentles, A. J., Sperinde, G. V., Edalati, A., Hadeiba, H. A., Alizadeh, A. A., Butcher, et al
2012; 209 (8): 1427-1435
 - **HIGH PD-1 EXPRESSION AND SUPPRESSED EFFECTOR CYTOKINE SIGNALING DISTINGUISH T CELLS INFILTRATING FOLLICULAR LYMPHOMA TUMORS FROM PERIPHERAL T CELLS**
Myklebust, J. H., Irish, J., Brody, J., Czerwinski, D., Houot, R., Kohrt, H., Timmerman, J., Green, M., Delabie, J., Kolstad, A., Alizadeh, A., Levy, R. FERRATA STORTI FOUNDATION.2012: 121
 - **A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma** *LEUKEMIA & LYMPHOMA*
Warsch, S., Hosein, P. J., Maeda, L. S., Alizadeh, A. A., Lossos, I. S.
2012; 53 (7): 1299-1305
 - **The chemoattractant chemerin as a natural tumor suppressive cytokine.** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Pachynski, R. K., Zabel, B., Tejada, N., Monnier, J., Holzer, A. K., Gentles, A., Kohrt, H. E., Hadeiba, H., Alizadeh, A. A., Butcher, E.
AMER SOC CLINICAL ONCOLOGY.2012
 - **The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Willingham, S. B., Volkmer, J., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., Lovelace, P., Scheeren, F. A., Chao, et al
2012; 109 (17): 6662-6667
 - **First Isolation of Cryptococcus uzbekistanensis from an Immunocompromised Patient with Lymphoma** *JOURNAL OF CLINICAL MICROBIOLOGY*
Powel, M. S., Alizadeh, A. A., Budvytiene, I., Schaenman, J. M., Banaei, N.
2012; 50 (3): 1125-1127
 - **Three differentiation states risk-stratify bladder cancer into distinct subtypes (vol 109, pg 2078, 2012)** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Volkmer, J., Sahoo, D., Chin, R. K., Ho, P. L., Tang, C., Kurtova, A. V., Willingham, S. B., Pazhanisamy, S. K., Contreras-Trujillo, H., Storm, T. A., Lotan, Y., Beck, A. H., Chung, et al
2012; 109 (9): 3600-3600
 - **Three differentiation states risk-stratify bladder cancer into distinct subtypes** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Volkmer, J., Sahoo, D., Chin, R. K., Ho, P. L., Tang, C., Kurtova, A. V., Willingham, S. B., Pazhanisamy, S. K., Contreras-Trujillo, H., Storm, T. A., Lotan, Y., Beck, A. H., Chung, et al
2012; 109 (6): 2078-2083
 - **Treatment advances have not improved the early death rate in acute promyelocytic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., Medeiros, B. C.
2012; 97 (1): 133-136
 - **Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies (vol 14, R25, 2012)** *ARTHRITIS RESEARCH & THERAPY*
Liu, C. L., Tansombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., Alizadeh, A. A., Utz, P. J.
2012; 14 (4)
 - **Correction: Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies.** *Arthritis research & therapy*
Liu, C. L., Tansombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., Alizadeh, A. A., Utz, P. J.
2012; 14 (4): 403-?

- **Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies** *ARTHRITIS RESEARCH & THERAPY*
Liu, C. L., Tangsombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., Alizadeh, A. A., Utz, P. J.
2012; 14 (1)
- **Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J., Klinger, M., Faham, M., Advani, R., Kohrt, H. E., Alizadeh, A. A., Negrin, R. S., Weng, W., Sheehan, et al
AMER SOC HEMATOLOGY.2011: 1323-23
- **Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia**
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A. A., Bates, J., Sekeres, M. A., Coutre, S. E., Kalaycio, M., Sobecks, R., Copelan, E., Advani, et al
AMER SOC HEMATOLOGY.2011: 1095
- **HGAL-a Germinal Center Specific Protein, Enhances B-Cell Receptor Signaling by Activation of Syk, Leading to Follicular Lymphoproliferation**
Jiang, X., Romero-Camarero, I., Lu, X., Vicente-Duenas, C., Gonzalez-Herrero, I., Flores, T., Luis Garcia, J., McNamara, G., Kunder, C., Natkunam, Y., Segura, V., Fontan-Gabas, L., Martinez-Climent, et al
AMER SOC HEMATOLOGY.2011: 269
- **A few good genes Simple, biologically motivated signatures for cancer prognosis** *CELL CYCLE*
Gentles, A. J., Alizadeh, A. A.
2011; 10 (21): 3615-3616
- **A proteomic approach for the identification of novel lysine methyltransferase substrates** *EPIGENETICS & CHROMATIN*
Levy, D., Liu, C. L., Yang, Z., Newman, A. M., Alizadeh, A. A., Utz, P. J., Gozani, O.
2011; 4
- **Utility of positron emission tomography scans in mantle cell lymphoma** *AMERICAN JOURNAL OF HEMATOLOGY*
Hosein, P. J., Pastorini, V. H., Paes, F. M., Eber, D., Chapman, J. R., Serafini, A. N., Alizadeh, A. A., Lossos, I. S.
2011; 86 (10): 841-845
- **Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors** *HEMATOLOGICAL ONCOLOGY*
Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., Mitchell, B. S.
2011; 29 (3): 157-160
- **Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia** *CANCER CELL*
Alizadeh, A. A., Majeti, R.
2011; 20 (2): 135-136
- **Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment** *BLOOD*
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., Houot, R., Goldstein, M. J., Zhao, S., Natkunam, Y., Advani, R. H., Gascoyne, R. D., Briones, J., Tibshirani, et al
2011; 118 (5): 1350-1358
- **Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results.**
Brody, J., Advani, R., Weng, W., Czerwinski, D., Alizadeh, A. A., Kohrt, H. E., Negrin, R., Levy, R.
AMER SOC CLINICAL ONCOLOGY.2011
- **Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Jan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentles, A. J., Weissman, I. L., Majeti, R.
2011; 108 (12): 5009-5014
- **Leukemic Stem Cell Gene Expression Signature and Clinical Outcomes in Acute Myeloid Leukemia Reply** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Gentles, A. J., Majeti, R., Alizadeh, A. A.

2011; 305 (11): 1094

- **CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies** *BLOOD*
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Mueller, A., Pachynski, R., Czerwinski, D., Coutre, S., Chao, M. P., Chen, L., Tedder, et al
2011; 117 (8): 2423-2432
- **Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia** *CANCER RESEARCH*
Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., Majeti, R.
2011; 71 (4): 1374-1384
- **NONINVASIVE PREDICTION OF GRAFT-VERUS-HOST DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BY GENE EXPRESSION PROFILING**
Kohrt, H. E., Li, L., Alizadeh, A. A., Heish, S., Goldstein, M. J., Strober, S., Sarwal, M., Lowsky, R.
ELSEVIER SCIENCE INC.2011: S336
- **Expression of CD137 Protein in Select Hematopoietic Tumors: Implications for Anti-CD137 Immunomodulatory Therapy**
Anderson, M. W., Freud, A. G., Zhao, S., Alizadeh, A. A., Kohrt, H. E., Warnke, R., Levy, R., Natkunam, Y.
NATURE PUBLISHING GROUP.2011: 285A
- **Expression of CD137 Protein in Select Hematopoietic Tumors: Implications for Anti-CD137 Immunomodulatory Therapy**
Anderson, M. W., Freud, A. G., Zhao, S., Alizadeh, A. A., Kohrt, H. E., Warnke, R., Levy, R., Natkunam, Y.
NATURE PUBLISHING GROUP.2011: 285A
- **Mixed Phenotype Acute Leukemia (MPAL): A Study of 61 Cases Using WHO and EGIL Criteria**
Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., Arber, D. A.
NATURE PUBLISHING GROUP.2011: 328A
- **Mixed Phenotype Acute Leukemia (MPAL): A Study of 61 Cases Using WHO and EGIL Criteria**
Weinberg, O. K., Seetharam, M., Ren, L., Alizadeh, A., Arber, D. A.
NATURE PUBLISHING GROUP.2011: 328A
- **Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Gentles, A. J., Plevritis, S. K., Majeti, R., Alizadeh, A. A.
2010; 304 (24): 2706-2715
- **Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47** *SCIENCE TRANSLATIONAL MEDICINE*
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., Majeti, R., Weissman, I. L.
2010; 2 (63)
- **NF-kappa B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Myklebust, J. H., Irish, J. M., Brody, J., Alizadeh, A. A., Czerwinski, D., Houot, R., Kohrt, H. E., Kolstad, A., Levy, R.
AMER SOC HEMATOLOGY.2010: 67-68
- **A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes**
Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., Mitchell, B. S.
AMER SOC HEMATOLOGY.2010: 788
- **Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Goldstein, M. J., Zhao, S., Natkunam, Y., Advani, R., Gascoyne, R. D., Briones, J., Tibshirani, R. J., Myklebust, et al
AMER SOC HEMATOLOGY.2010: 836-37
- **Noninvasive Prediction of Graft-Verus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Kohrt, H. E., Li, L., Alizadeh, A. A., Goldstein, M. J., Strober, S., Sarwal, M., Lowsky, R.

AMER SOC HEMATOLOGY.2010: 393–94

- **Self-Antigen Recognition by the B Cell Receptors of Follicular Lymphoma** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Layn, K., Alizadeh, A. A., Kattah, N., Levy, S., Levy, R.
AMER SOC HEMATOLOGY.2010: 1678–79
- **Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Alizadeh, A. A., Anderson, M., Kohrt, H. E., Shyam, R. M., Bangs, C. D., Cherry, A. M., Advani, R., Natkunam, Y., Levy, R.
AMER SOC HEMATOLOGY.2010: 1291–92
- **Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience** *AMERICAN JOURNAL OF HEMATOLOGY*
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Alizadeh, A. A., Medeiros, B. C.
2010; 85 (11): 877-881
- **B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Irish, J. M., Myklebust, J. H., Alizadeh, A. A., Houot, R., Sharman, J. P., Czerwinski, D. K., Nolan, G. P., Levy, R.
2010; 107 (29): 12747-12754
- **Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha** *LEUKEMIA & LYMPHOMA*
Alizadeh, A. A., Bohlen, S. P., Lossos, C., Martinez-Climent, J. A., Ramos, J. C., Cubedo-Gil, E., Harrington, W. J., Lossos, I. S.
2010; 51 (7): 1200-1216
- **Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)** *LEUKEMIA RESEARCH*
Medeiros, B. C., Kohrt, H. E., Arber, D. A., Bangs, C. D., Cherry, A. M., Majeti, R., Kogel, K. E., Azar, C. A., Patel, S., Alizadeh, A. A.
2010; 34 (5): 594-597
- **Noninvasive Prediction of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling.** *10th American Transplant Congress*
Li, L., Kohrt, H., Heish, S., Alizadeh, A., Laport, G., Shizuru, J., Negrin, R., Strober, S., Lowsky, R., Sarwal, M.
WILEY-BLACKWELL.2010: 483–483
- **Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS)** *Blood (e-Letter)*
Kohrt HE, Patel S, Ho M, Owen T, Majeti R, Gotlib JR, Coutre SE, Medeiros BC, Alizadeh AA.
2010; 113 (1): 28-36
- **Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Chao, M. P., Alizadeh, A. A., Tang, C. Z., Myklebust, J. H., Varghese, B., Jan, M., Levy, R., Weissman, I. L., Majeti, R.
AMER SOC HEMATOLOGY.2009: 1063–64
- **High Risk of Early Mortality in Adult Patients with Acquired Hemophagocytic Lymphohistiocytosis.**
Logan, A. C., Su, R., George, T. I., Kohrt, H. E., Medeiros, B. C., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2009: 554
- **Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Alizadeh, A. A., Gentes, A. J., Plevritis, S. K., Levy, R.
AMER SOC HEMATOLOGY.2009: 1153–53
- **Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Alizadeh, A. A., Gentes, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Talreja, N., Shyam, R., Natkunam, Y., Gascoyne, R. D., Briones, J., Advani, R., Lossos, I. S., Levy, et al
AMER SOC HEMATOLOGY.2009: 258–58

- **Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., Coutre, S., Medeiros, B. C., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2009: 646–47
- **Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., Medeiros, B. C.
AMER SOC HEMATOLOGY.2009: 420–21
- **A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Myklebust, J. H., Irish, J. M., Houot, R., Brody, J., Czerwinski, D. K., Alizadeh, A. A., Kolstad, A., Levy, R.
AMER SOC HEMATOLOGY.2009: 316–16
- **Therapeutic Potential of Anti-CD137 Antibody in Lymphoma** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., Irish, J. M., Torchia, J. A., Kolstad, A., Chen, L., Levy, R.
AMER SOC HEMATOLOGY.2009: 301–2
- **Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion** *BLOOD*
Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., Irish, J. M., Torchia, J. A., Kolstad, A., Chen, L., Levy, R.
2009; 114 (16): 3431-3438
- **CD47 IS AN ADVERSE PROGNOSTIC FACTOR IN NON-HODGKIN LYMPHOMA AND A THERAPEUTIC ANTIBODY TARGET THAT SYNERGIZES WITH RITUXIMAB** *38th Annual Scientific Meeting of the ISEH-Society-for-Hematology-and-Stem-Cells*
Chao, M. P., Alizadeh, A., Tang, C. Z., Jan, M., Levy, R., Majeti, R., Weissman, I. L.
ELSEVIER SCIENCE INC.2009: S8–S9
- **CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells** *CELL*
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., Weissman, I. L.
2009; 138 (2): 286-299
- **A stem cell-like signature predicts histological transformation and influences survival in follicular lymphoma patients**
Gentles, A., Alizadeh, A., Lee, S., Shahbaba, B., Shachaf, C., Levy, R., Koller, D., Plevritis, S.
AMER ASSOC CANCER RESEARCH.2009
- **A pluripotency signature predicts histological transformation and influences survival in follicular lymphoma patients** *Blood*
Gentles AJ**, Alizadeh AA** (contributed equally), Lee S, Myklebust JH, Shachaf CM, Shahbaba B, Levy R, Koller D, Plevritis SK.
2009
- **Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.** *Clinical advances in hematology & oncology : H&O*
Alizadeh, A. A., Advani, R. H.
2008; 6 (12): 899-909
- **CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Weissman, I. L.
AMER SOC HEMATOLOGY.2008: 284–84
- **LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study.** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Advani, R., Tareja, N., Tibshirani, R., Zhao, S., Alizadeh, A., Briones, J., Bordes, R., Cohen, J., Horning, S., Levy, R., Lossos, I. S., Natkunam, Y.
AMER SOC HEMATOLOGY.2008: 1291–91
- **Double trouble in follicular lymphoma: A rare and unusual synergy of oncogenes in the germinal center** *LEUKEMIA & LYMPHOMA*
Alizadeh, A. A., Lossos, I. S.
2008; 49 (3): 377-380
- **Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan-virus microarray** *JOURNAL OF CLINICAL MICROBIOLOGY*

- Chiu, C. Y., Alizadeh, A. A., Rouskin, S., Merker, J. D., Yeh, E., Yagi, S., Schnurr, D., Patterson, B. K., Ganem, D., DeRisi, J. L.
2007; 45 (7): 2340-2343
- **Cell-type specific gene expression profiles of leukocytes in human peripheral blood** *BMC GENOMICS*
Palmer, C., Diehn, M., Alizadeh, A. A., Brown, P. O.
2006; 7
 - **Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas** *BLOOD*
Lu, X. Q., Nechushtan, H., Ding, F. Y., Rosado, M. F., Singal, R., Alizadeh, A. A., Lossos, I. S.
2005; 105 (7): 2924-2932
 - **Distinct IL-4 intracellular signaling in germinal center B-cell like and activated B-cell like diffuse large B-cell lymphoma: Novel opportunities for therapeutic interventions.**
Lossos, I. S., Lu, X. Q., Ding, F. Y., Rosado, M., Alizadeh, A. A., Nechushtan, H.
AMER SOC HEMATOLOGY.2004: 73A-74A
 - **AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity** *LEUKEMIA*
Lossos, I. S., Levy, R., Alizadeh, A. A.
2004; 18 (11): 1775-1779
 - **Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response** *BLOOD*
Rosenwald, A., Chuang, E. Y., Davis, R. E., Wiestner, A., Alizadeh, A. A., Arthur, D. C., Mitchell, J. B., Marti, G. E., Fowler, D. H., Wilson, W. H., Staudt, L. M.
2004; 104 (5): 1428-1434
 - **Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes** *NEW ENGLAND JOURNAL OF MEDICINE*
Lossos, I. S., Czerwinski, D. K., Alizadeh, A. A., Wechser, M. A., Tibshirani, R., Botstein, D., Levy, R.
2004; 350 (18): 1828-1837
 - **Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds.** *PLoS biology*
Chang, H. Y., Sneddon, J. B., Alizadeh, A. A., Sood, R., West, R. B., Montgomery, K., Chi, J., van de Rijn, M., Botstein, D., Brown, P. O.
2004; 2 (2): E7-?
 - **Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence for the existence of distinctive pathways relevant to disease**
Kasperkovitz, P., Verbeet, N. L., Smeets, T., Tak, P. P., Huizinga, T., Baltus, B., Timmer, T., Pieterman, E., Fero, M., Firestein, G. S., Alizadeh, A. A., van der Pouw Kraan, T. C., Verweij, et al
BIOMED CENTRAL LTD.2004: S25
 - **Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds** *PLOS BIOLOGY*
Chang, H. Y., Sneddon, J. B., Alizadeh, A. A., Sood, R., West, R. B., Montgomery, K., Chi, J. T., van de Rijn, M., Botstein, D., Brown, P. O.
2004; 2 (2): 206-214
 - **Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock** *LANCET*
Pathan, N., Hemingway, C. A., Alizadeh, A. A., Stephens, A. C., Boldrick, J. C., Oragui, E. E., McCabe, C., Welch, S. B., Whitney, A., O'Gara, P., Nadel, S., Relman, D. A., Harding, et al
2004; 363 (9404): 203-209
 - **Prediction of survival in diffuse large B-Cell lymphoma (DLBCL) based on the expression of six genes.**
Lossos, L. S., Czerwinski, D., Tibshirani, R., Wechser, M., Alizadeh, A. A., Botstein, D., Levy, R.
AMER SOC HEMATOLOGY.2003: 391A
 - **T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression** *PLOS BIOLOGY*
Roose, J. P., Diehn, M., Tomlinson, M. G., Lin, J., Alizadeh, A. A., Botstein, D., Brown, P. O., Weiss, A.
2003; 1 (2): 271-287
 - **T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression.** *PLoS biology*

- Roose, J. P., Diehn, M., Tomlinson, M. G., Lin, J., Alizadeh, A. A., Botstein, D., Brown, P. O., Weiss, A.
2003; 1 (2): E53-?
- **Rheumatoid arthritis is a heterogeneous disease - Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues** *ARTHRITIS AND RHEUMATISM*
Kraan, T. C., van Gaalen, F. A., Kasperkovitz, P. V., Verbeet, N. L., Smeets, T. J., Kraan, M. C., Fero, M., Tak, P. P., Huizinga, T. W., Pieterman, E., Breedveld, F. C., Alizadeh, A. A., Verweij, et al
2003; 48 (8): 2132-2145
 - **Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations** *BLOOD*
Martinez-Climent, J. A., Alizadeh, A. A., Segraves, R., Blesa, D., Rubio-Moscardo, F., Albertson, D. G., Garcia-Conde, J., Dyer, M. J., Levy, R., Pinkel, D., Lossos, I. S.
2003; 101 (8): 3109-3117
 - **Individuality and variation in gene expression patterns in human blood** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Whitney, A. R., Diehn, M., Popper, S. J., Alizadeh, A. A., Boldrick, J. C., Relman, D. A., Brown, P. O.
2003; 100 (4): 1896-1901
 - **HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma** *BLOOD*
Lossos, I. S., Alizadeh, A. A., Rajapaksa, R., Tibshirani, R., Levy, R.
2003; 101 (2): 433-440
 - **Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling** *N Engl J Med*
Sarwal M, Chen X, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Alizadeh AA, Masek M, Diehn, M, Salvatierra O Jr, Brown PO
2003; 349 (2): 125-38
 - **Comparison of molecular abnormalities in bronchial brushings and tumor touch preps: The potential use of fluorescence in situ hybridization (FISH) as a predictive marker in early stage lung carcinomas**
Barkan, G. A., Caraway, N. P., Zaidi, T., Alizadeh, A., Johnston, D., Jiang, F., Katz, R. L.
NATURE PUBLISHING GROUP.2003: 59A
 - **SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data** *NUCLEIC ACIDS RESEARCH*
Diehn, M., Sherlock, G., Binkley, G., Jin, H., Matese, J. C., Hernandez-Boussard, T., Rees, C. A., Cherry, J. M., Botstein, D., Brown, P. O., Alizadeh, A. A.
2003; 31 (1): 219-223
 - **Caspase-12 expression is markedly reduced in NF-E2(-/-) megakaryocytes and caspase-12(-/-) platelets exhibit a defect in integrin alpha IIb beta 3 inside-out signaling.**
Kerrigan, S. W., Murphy, R. P., Alizadeh, A., Diehn, M., Shattil, S. J., Leavitt, A. D.
AMER SOC HEMATOLOGY.2002: 13A
 - **GAL is a novel IL-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.**
Lossos, I. S., Alizadeh, A. A., Rajapaksa, R., Tibshirani, R., Levy, R.
AMER SOC HEMATOLOGY.2002: 90A-91A
 - **Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation (vol 99, pg 11796, 2002)** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Diehn, M., Alizadeh, A. A., Rando, O. J., Liu, C. L., Stankunas, K., Botstein, D., Crabtree, G. R., Brown, P. O.
2002; 99 (23): 15245
 - **Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays** *AMERICAN JOURNAL OF PATHOLOGY*
Liu, C. L., Prapong, W., Natkunam, Y., Alizadeh, A., Montgomery, K., Gilks, C. B., van de Rijn, M.
2002; 161 (5): 1557-1565
 - **Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Diehn, M., Alizadeh, A. A., Rando, O. J., Liu, C. L., Stankunas, K., Botstein, D., Crabtree, G. R., Brown, P. O.
2002; 99 (18): 11796-11801

- **Distinctive gene expression profiles in synovial tissue from rheumatoid arthritis patients by cDNA microarray analysis.**
Kraan, T. C., van Gaalen, F. A., Alizadeh, A. A., Fero, M., Huizinga, T. W., Pieterman, E., Breedveld, F. C., Botstein, D., Brown, P. O., Verweij, C. L.
WILEY.2002: S266-S267
- **Rheumatoid arthritis is a heterogeneous disease: Discovery of distinctive gene expression profiles in rheumatoid synovia.**
Verweij, C. L., Kraan, T. T., van Gaalen, F. A., Kasperkovitz, P. V., Smeets, T. J., Alizadeh, A. A., Tak, P. P., Huizinga, T. W., Pieterman, E., Breedveld, F. C., Botstein, D., Brown, P. O.
WILEY.2002: S266
- **Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Lossos, I. S., Alizadeh, A. A., Diehn, M., Warnke, R., Thorstenson, Y., Oefner, P. J., Brown, P. O., Botstein, D., Levy, R.
2002; 99 (13): 8886-8891
- **The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile** *BLOOD*
Huang, J. Z., Sanger, W. G., Greiner, T. C., Staudt, L. M., Weisenburger, D. D., Pickering, D. L., Lynch, J. C., Armitage, J. O., Wamke, R. A., Alizadeh, A. A., Lossos, I. S., Levy, R., Chan, et al
2002; 99 (7): 2285-2290
- **Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation** *NUCLEIC ACIDS RESEARCH*
Yang, Y. H., Dudoit, S., Luu, P., Lin, D. M., Peng, Ngai, J., Speed, T. P.
2002; 30 (4): e15
- **In vivo regulation of human skeletal muscle gene expression by thyroid hormone** *GENOME RESEARCH*
Clement, K., Viguier, N., Diehn, M., Alizadeh, A., Barbe, P., Thalamas, C., Storey, J. D., Brown, P. O., Barsh, G. S., Langin, D.
2002; 12 (2): 281-291
- **Stereotyped and specific gene expression programs in human innate immune responses to bacteria** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Boldrick, J. C., Alizadeh, A. A., Diehn, M., Dudoit, S., Liu, C. L., Belcher, C. E., Botstein, D., Staudt, L. M., Brown, P. O., Relman, D. A.
2002; 99 (2): 972-977
- **Discovery of distinctive gene expression profiles in human arthritides by cDNA micro-array analysis**
Kraan, T., van Gaalen, F. A., Kasperkovitz, P., Verbeet, N., Alizadeh, A. A., Fero, M., Huizinga, T. J., Pieterman, E., Breedveld, F. C., Staudt, L. M., Botstein, D., Brown, P. O., Verweij, et al
BIOMED CENTRAL LTD.2002
- **Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia** *JOURNAL OF EXPERIMENTAL MEDICINE*
Rosenwald, A., Alizadeh, A. A., Widhopf, G., Simon, R., Davis, R. E., Yu, X., Yang, L. M., Pickeral, O. K., Rassenti, L. Z., Powell, J., Botstein, D., Byrd, J. C., Grever, et al
2001; 194 (11): 1639-1647
- **Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.** *The Journal of experimental medicine*
Rosenwald, A., Alizadeh, A. A., Widhopf, G., Simon, R., Davis, R. E., Yu, X., Yang, L., Pickeral, O. K., Rassenti, L. Z., Powell, J., Botstein, D., Byrd, J. C., Grever, et al
2001; 194 (11): 1639-47
- **Higher-grade transformed follicle center lymphomas (FCL): Gene expression profiling comparison to pre-transformed FCL and to de novo diffuse large B-cell lymphomas (DLBCL).**
Lossos, I. S., Alizadeh, A. A., Diehn, M., Warnke, R., Brown, P. O., Botstein, D., Levy, R.
AMER SOC HEMATOLOGY.2001: 722A
- **Genetic approaches using primary megakaryocytes to identify effectors of platelet integrin signaling**
Shattil, S. J., Bertoni, A., Eto, K., Murphy, R., Pampori, N., Shiraga, M., Stuhlmann, H., Tadokoro, S., Kerrigan, S., Alizadeh, A., Diehn, M., Brown, P. O., Leavitt, et al
AMER SOC CELL BIOLOGY.2001: 270A
- **Towards a novel classification of human malignancies based on gene expression patterns** *JOURNAL OF PATHOLOGY*

- Alizadeh, A. A., Ross, D. T., Perou, C. M., van de Rijn, M.
2001; 195 (1): 41-52
- **Discovery of distinctive gene expression profiles in human arthritides by cDNA microarray analysis.**
Verweij, C. L., Kraan, T. C., van Galen, F., Alizadeh, A. A., Fero, M., Huizinga, T. W., Pieterman, E., Breedveld, F. C., Staudt, L. M., Botstein, D., Brown, P. O.
WILEY-LISS.2001: S398
 - **Genomic analysis of renal allograft dysfunction using cDNA microarrays** *18th World Congress of the Transplantation-Society*
Sarwal, M., Chang, S., Barry, C., Chen, X., Alizadeh, A., Salvatierra, O., BROWN, P.
ELSEVIER SCIENCE INC.2001: 297-98
 - **Supervised harvesting of expression trees** *GENOME BIOLOGY*
Hastie, T., Tibshirani, R., Botstein, D., Brown, P.
2001; 2 (1)
 - **BCL-6 protein expression predicts improved survival in patients with diffuse large B-cell lymphoma**
Natkunam, Y., Warnke, R., Alizadeh, A., Tibshirani, R., Horning, S., van de Rijn, M.
NATURE PUBLISHING GROUP.2001: 173A
 - **BCL-6 protein expression predicts improved survival in patients with diffuse large B-cell lymphoma**
Natkunam, Y., Warnke, R., Alizadeh, A., Tibshirani, R., Horning, S., van de Rijn, M.
NATURE PUBLISHING GROUP.2001: 173A
 - **Gene expression profiling of rheumatoid synovitis using cDNA microarrays.**
Verweij, C. L., van der Kraan, C. T., Alizadeh, A. A., Fero, M., Huizinga, T. W., Pieterman, E., Firestein, G. S., Breedveld, F. C., Staudt, L. M., Botstein, D., Brown, P. O.
LIPPINCOTT WILLIAMS & WILKINS.2000: S160
 - **Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Lossos, I. S., Alizadeh, A. A., Eisen, M. B., Chan, W. C., Brown, P. O., Botstein, D., Staudt, L. M., Levy, R.
2000; 97 (18): 10209-10213
 - **Exploring gene expression signatures of host responses to infection**
Boldrick, J. C., Belcher, C. E., Alizadeh, A. A., Liu, C. L., Diehn, M., Brown, P. O., Relman, D. A.
OXFORD UNIV PRESS INC.2000: 218-18
 - **Examining the living genome in health and disease with DNA microarrays** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Diehn, M., Alizadeh, A. A., Brown, P. O.
2000; 283 (17): 2298-2299
 - **Genomic-scale gene expression profiling of normal and malignant immune cells** *CURRENT OPINION IN IMMUNOLOGY*
Alizadeh, A. A., Staudt, L. M.
2000; 12 (2): 219-225
 - **'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns.** *Genome biology*
Hastie, T., Tibshirani, R., Eisen, M. B., Alizadeh, A., Levy, R., Staudt, L., Chan, W. C., Botstein, D., BROWN, P.
2000; 1 (2): RESEARCH0003-?
 - **Gene expression in large B-cell lymphoma using cDNA microarray technology.**
Chan, W. C., Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H., Tran, T., Powell, J. I., Yang, L., Greiner, T. C., Weisenburger, D. D., Armitage, J. O., Marti, et al
AMER SOC HEMATOLOGY.1999: 698A-698A
 - **Genome-wide analysis of DNA copy-number changes using cDNA microarrays** *NATURE GENETICS*
Pollack, J. R., Perou, C. M., Alizadeh, A. A., Eisen, M. B., Pergamenschikov, A., Williams, C. F., Jeffrey, S. S., Botstein, D., Brown, P. O.
1999; 23 (1): 41-46
 - **The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes** *64th Symposia: Signaling and Gene Expression in the Immune System*

Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H., Tran, T., Powell, J. I., Yang, L., Marti, G. E., Moore, D. T., Hudson, J. R., Chan, W. C., Greiner, et al

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT.1999: 71-78

- **Probing lymphocyte biology by genomic-scale gene expression analysis** *JOURNAL OF CLINICAL IMMUNOLOGY*

Alizadeh, A., Eisen, M., Botstein, D., Brown, P. O., Staudt, L. M.

1998; 18 (6): 373-379

- **DNA microarrays as "microscopes" for watching a genome in action**

Brown, P. O., Botstein, D., Alizadeh, A., Derisi, J., Diehn, M., Eisen, M., Iyer, Perou, C., Pollack, J., Ross, D., Spellman, P., Staudt, L.

AMER SOC CELL BIOLOGY.1998: 2A